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A decade of lessons learned: PML pathogenesis and risks associated with therapies for MS  
 
Introduction 
Over one decade has passed since the first report of progressive multifocal leukoencephalopathy (PML) in several multiple sclerosis 
(MS) patients receiving natalizumab in a clinical trial. This monoclonal antibody to α4 integrins blocks inflammatory cell entry into 
the brain and blocked MS related clinical relapses. The occurrence of two very different demyelinating diseases in the brain of a single 
patient was unanticipated since PML and MS have very little in common except the destruction of myelin.  PML is a viral induced 
lytic brain infection while the etiology of relapsing/remitting MS is an autoimmune response. PML in these MS patients was quickly 
associated with natalizumab, primarily because MS patients had been treated with other immune therapies for decades without reports 
of PML.
1-4
 Subsequently, there have been several  rare reports of PML in MS patients on other therapies like dimethyl fumarates and 
fingolimod. 
5-9
 The initial incidence of PML in natalizumab treated MS patients in the phase 3 trial was estimated to be 1 in 1000.
4
 
Ten years later, >750 PML cases have been reported with >20% fatality rate, and substantial morbidity to survivors. (Biogen, Tysabri 
Safety Update, September 2017, https://medinfo.biogen.com/secure/pmlresource)   The incidence in patients on >24 months treatment,  
antibody evidence of JC Virus (JCV) exposure, and prior immunosuppressant treatment has reached at least 1 in 70, an incidence 
much higher than any other opportunistic infection in this setting.,
10,11
 Use of a more quantitative antibody index has recently yielded 
estimates of 2.7% after 72 months natalizumab therapy with prior immunosuppressant exposure.
12
  The incidence of PML in MS 
patients on other immune modulating therapies is much less, perhaps 1 in 10,000 to 1 in 100,000. So what have we learned from this 
experience on the pathogenesis of PML and how might that knowledge be applied to distinguishing therapy associated risks of PML 
that would help establish evidenced based monitoring of patients and inform the selection of effective MS treatments for individual 
patients?  There are several areas that surfaced from investigations on PML in MS patients that will be explored in this review: 1. The 




PML cases regardless of various underlying diseases. 2. the central role of magnetic resonance imaging (MRI) in the diagnosis of 
PML, monitoring treated patients to control its morbidity and advancing our understanding of aspects of its pathophysiology, and 3. 
new insights of clinical value of early PML detection.  
 
JC Virus infection and PML pathogenesis 
To understand the complexities of the pathogenesis of PML, it is important to detail some of the background and biology of JCV 
infection leading to PML. First described in 1958, PML is usually characterized as a rare disease caused by JC Virus, named from the 
initials of the first patient from whom the virus was isolated in 1971.
13
  PML develops in patients with compromised immune systems, 
particularly cell mediated immune responses. Until the mid 1980s, PML was reported in patients with underlying neoplastic diseases, 
mostly lymphoproliferative diseases, and a few organ transplant patients treated with immune suppression for graft protection.
14
 In the 
mid- 1980s, HIV-1 infection became the predominate risk with up to 5% of AIDS deaths associated with PML. Effective antiretroviral 
therapy and earlier initiation to avert severe immunodeficiency have decreased the risk in HIV infected patients to <1%  . 
15,16
 Using a 
Pubmed search in 2017, we found that since 2005, reports of PML in patients with MS and other underlying diseases, and therapies to 
treat them, have increased 10 fold suggesting a greater awareness of PML based on clinical evaluation, MRI imaging and use of 
laboratory tests for JCV DNA and anti JCV antibody. It may be time now to consider PML not as just a rare disease but as a 
substantial neurological complication in certain high risk populations.   
The pathophysiology of JCV in human hosts leading to PML is outlined in Figure 1 following steps 1 through 10 with additional 
details in Table 1, further annotated in Table 1. JCV has a narrow cellular host range and a variable effect on the organs it infects. 
Infection in human endothelial cells in the kidney
17-20
 and in cells of hematopoietic lineage like CD34+, B cell phenotypes, CD19+ 
and CD20+ have little  pathological effect making infection of hosts a silent event.
21
  In the brain however, the multiplication in 
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oligodendrocytes is lytic and results in PML with devastating clinical consequences. Infection of the neurons in granular cell layer in 
the cerebellum can also result in a symptomatic neuronopathy. 
22
 
For cells to be susceptible to JCV infection, they need to express DNA binding proteins that recognize the viral genome, non-coding 
control region (NCCR) that initiates viral DNA replication and transcription for RNA and eventually protein synthesis (Figure 1steps 
6,7/Table 1). There are a number of such transcription factors that are critical to JCV multiplication. The noncoding control region 
(NCCR) nucleotide sequences are represented in two arrangements. The archetype NCCR is comprised of approximately 200 linear 
nucleotides in virions excreted in the urine, figure 1,step 2,which occurs in about 30% of the population. This ‘archetype’ variant is 
generally considered non-pathogenic in kidney or, if identified, in other compartments like plasma/serum and even in brain. Virus 
isolated from PML patient’s brain, like the index patient JC, became known as the prototype variant associated with pathogenic PML 
brain and CSF.
23
 These approximately 200 NCCR nucleotides are not arranged linearly but in direct tandem repeats of 98 nucleotide 
base pairs or other arrangements but always showing duplications. It is thought that the prototype variant is derived from the archetype 
by deletion and duplication. The tissue compartment or cell type in which a ‘rearrangement’ of the NCCR from archetype to prototype 
could take place is still not known but lymphoid cells are a very probable host. (Fig 1, steps 4,5)
24-27
 While there are no specific 
studies in cell culture or in patients that show that such a rearrangement can take place, there are very compelling indirect data 
supporting such a mechanism. New evidence even implicates Epstein Barr virus coinfection as possible catalyst in the nucleotide 
transition of the archetype to the prototype variants.
28
 
Sero-epidemiological studies show a global distribution of JCV with an estimated rate greater than 50% of the adult population having 
been exposed. 
29
The initial site of infection is still not known but thought to be ingestion or perhaps respiratory inhalation. (Figure 1, 
step1,) Contact with JCV most commonly results in a subclinical infection during which individuals develop antibodies and cell 
mediated immune responses (Table 1).
30,31
 The serology test used for these studies had been hemagglutination inhibition( HI) based on 
the virions’ ability to aggregate human type O erythrocytes. Anti JCV antibody would inhibit that reaction. Using this assay, a recent 
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 This observation has been verified with the development of ELISA assays that use recombinant produced VP-1 
and not whole virions.
33
  VP-1 is the major capsid protein making the outer structure of the viral icosahedral particle and functions in 
cell attachment. The commercial Quest Diagnostic assay, Stratify
TM




 uses the 
same VP-1 produced by recombinant technology.
34
 Based on these assays, approximately 55% of MS patients are JCV seropositive. 
There are patients who ‘seroconvert’ from negative to positive at a higher rate than those who ‘serorevert’.  The rates of 
seroconversion in either direction may range from 3% to as high as 10% over a course of years.
35
 This observation can complicate 
testing for anti JCV antibody as part of a risk mitigation program for PML since presence of antibody indicates prior viral infection. 
An increase in antibody titer or index indicates a history of active infection resulting from a persistent or reactivation of latent 
infection. An algorithm using the antibody index, calculated using the optical density in the Stratify ELISA assay, shows a correlation 
with PML risk.
36
 A substantial rise in antibody has been identified in PML patients both in their plasma and CSF for weeks or months 
after diagnosis.
37
 There are also reports of an increase in antibody to JCV in natalizumab treated MS patients that is most likely due to 
release of a previous latent or persistent JCV infection with a subsequent antibody response. The value of regular intervals of anti JCV 
antibody monitoring is important but should be put into context. The antibody results indicate whether a patient has been exposed and 
if titers/index increases substantially may indicate that an active infection has taken place. However, reliance on antibody titers/index 
change is limited as illustrated by the apparent absence of increased titers in patients with prior immunosuppression. However, 
fundamental virology principles across most viruses that can become latent accept that individuals who have been exposed to a virus 
are at greater risk for disease from that virus than those who have not been.   
In addition, anti JCV antibodies may be directed to different regions of the primary capsid protein, VP-1, that could be unique to a 
particular patient. As is the situation with the viral NCCR, the VP-1 gene can be hypervariable producing a number of VP-1 proteins 
with different primary amino acid sequences compared with the prototype variant. This has been known for many years in the 
thorough description of the ‘JCV Type’ linking geographical locations with independent VP -1 genes and protein variants.38  So it is 
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not surprising that any one PML patient may have multiple representations of VP-1 protein at any one time. This observation had led 
to the hypothesis of VP-1 gene rearrangement that could result in a more ‘neurovirulent’ variant leading to PML.39,40 This observation 
warrants further investigation that would require ‘deep sequencing’ studies.41 However, it appears that PML patients are infected with 
the prototype VP-1 protein since that is the antigen used in the ELISA assays of commercial, academic and government laboratories. It 
is possible that immune escape of JCV VP-1 variants could occur due to either persistent JCV in cell compartments or mutations in the 
VP-1 gene to avoid immune recognition.
40
 This has been an area of new investigation in the last several years.  
However, antibodies to JCV may not result in protection against PML development (and are thus not necessarily neutralizing 
antibodies). There is ample in vitro data showing antibody made against JCV blocks virion adsorption to target cells that limits 
attachment and entry, thus reducing viral multiplication.  But there is little clinical evidence in healthy people or patients showing 
antibody may help control JCV infection.
42
 In fact nearly all individuals who persistently shed JCV in their urine are seropositive. 
Some seropositive individuals can even be viremic, and PML patients can have very high levels of CSF antibody in the presence of 
high viral DNA copy numbers.
43,44
 Consequently, CD4+ and CD8+ cytotoxic cell recognition of viral antigens probably play a more 
significant role against JCV infection. CD8+ cytotoxic T cells to JCV prototype VP-1 have been identified in PML and non-PML 
patients for many years.
45,46
 (Fig 1,step7) With the increase reported incidence of PML in MS patients treated with DMTs, newer 
studies have identified CD 4+ T cells as critical to control of JCV in natalizumab treated patients directed against the 4 major JCV 
proteins, T antigen, VP-1, VP-2, and agno. In addition, lack of CD 4+ cells and those releasing Il-10 were identified in natalizumab 
treated MS patients including one of the index cases who remained persistently JCV positive in CSF for years.
47
 CD 4+ T cells have 
also been cultured from brain tissue of PML patients that are directed to potential more neurotropic viral capsid proteins not identified 
by CD 4+ T cells in the periphery. These CD 4+ cells seemed necessary to stimulate cytotoxic CD8+ cells to function for clearance of 
JCV from the brain so perhaps were lacking in PML patients.  These laboratory and clinical studies have been undertaken directly in 
response to the need for a better understanding of the immune system role because of PML incidence in MS patients. Perhaps in 
further defining risk factors for PML, identifying CD 4+, CD8+ and other immune system cells for activity to JCV antigens would be 
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informative in the PML high risk patients. Unlike MS, the specific etiologic cause of PML is well known, JC Virus lytic infection of 
oligodendrocytes. To acquire a deeper understanding of the pathogenesis of PML, there needs to be a magnified focus on the virus 
including the stages of infection leading to oligodendrocyte cell death. (Figure 1, step 10) 
A case can be made that common pathophysiologic pathways explain the steps leading to PML, regardless of the underlying risk that 
allowed it. For example, some patients with T cell immune compromised systems may harbor JCV in a latent state in tissues like 
kidney, lymphoid organs like bone marrow, and possibly brain. Periodic JCV release from latency or even a persistent infection is 
poorly managed by the immune system so virus may enter the brain as free virions or through an infected cell (Figure 1, step 9/Table 
1). CD 4+ cells that do not adequately recognize JCV antigens have now become an important part of lack of immune surveillance
48
 
while cells in the B cell lineage have been implicated as possible carriers since JCV has been identified in CD 19 and CD 20 cells.
49
 
The brain is not the initial site of JCV infection and data on latency in brain are very limited. There have been reports of identification 
of JCV DNA in brain tissues of non-PML patients.
50
 In these reports, there was no evidence that the entire viral genome was present 
in order to initiate and sustain viral multiplication.   There is only one study that specifically investigated the presence of JCV DNA in 
MS brain tissue and found it absent.
51
 A multicenter study using blinded samples and controls of positive and negative brain tissues 
should be considered to determine the existence of latent JCV in the brain. However, at this point it is more  likely that release of 
latent JCV in the periphery, particularly the virulent variant, is a key factor. The kidney/urine derived variant is considered non-
virulent or at least less neurotropic, so the best candidate for latency is likely in lymphoid cells (Fig 1, step 4,5,Table 1). 
52
These cells 
can be hosts for rearrangement of the viral NCCR and perhaps gene rearrangement of the VP-1. They would be subject to factors that 
activate viruses like EBV that may even assist in JCV NCCR rearrangement from the archetype to the prototype by gene 
rearrangement and insertion as well as the potential to be targets for RAG 1 and RAG2 enzymatic mechanisms best known for their 





So a question becomes what unique features does natalizumab possess that no other therapy associated PML risk shares. Natalizumab 
associated PML patients are not systemically immune suppressed. Other opportunistic infections are not prominent, suggesting PML 
is a specifically enhanced problem rather than the result of broad immunosuppression. Further, it appears to require years for the risk 
to be manifest. These two factors highlight the need to understand PML pathogenesis beyond pure immune suppressive explanations. 
It may be over simplistic to suggest that lack of immune surveillance is the major underlying mechanism of PML in natalizumab 
treated MS patients. Even with immune reconstitution inflammatory syndrome (IRIS), some natalizumab treated PML patients 
continue to have detectable virus in CSF for months to years.
37
 We see two unique features of natalizumab that contribute to its special 
risk. One is that natalizumab forces migration of hematopioietic stem cells, CD34+ and precursors of B cells from the bone marrow 
(Figure 1, step 4). It shares this feature with efalizumab, the other monoclonal with highest risk of PML. The other is the temporal 
relationship of PML incidence after long term dosing, approximately 2 years or longer.  JCV can be latent/persistent in CD 34+ or 
preB cells in the bone marrow described by several laboratories
24,25,55
 and in culture models identifying DNA binding factors that act 
on the JCV transcription sites.
56
  These factors can also be found in CD 19 and CD 20 cells in the peripheral circulation. It is possible 
that the high percent of such cells forced out of the bone marrow for long periods would result in release of some latently infected 
cells (Figure 1, step 5). In those individuals, perhaps their immune system cells do not completely clear newly released virions 
particularly if remaining intracellular like EBV. But that observation does not account for the temporal correlation of the high 
incidence of PML after nearly 2 years of dosing. However, natalizumab also upregulates genes in a critical pathway for maturation of 
B cells, POU domain DNA transcription factors particularly Spi B that binds JCV NCCR. The time course of natalizumab effect on 
POU domain regulation is consistent with PML incidence. 
57,58
 The two characteristics only occurring in natalizumab, forced 
migration of cells from the bone marrow and temporal upregulation of factors that highly favor JCV growth match the current 
observations of  delayed PML incidence and focuses attention on the cause of PML, JC Virus cellular interactions leading to PML 
(Table 1, steps 5,6). While perhaps still premature, it is noteworthy to consider how laboratory analysis of these factors in immune 
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MRI Imaging for Early PML Detection/Diagnosis/Management 
 The approach to diagnosis of PML has been reviewed elsewhere, but routinely requires identification of active CNS pathology 
and JC virus in the brain.
61
  Brain imaging is a critical contributor to the diagnosis of PML.
61
 Indeed, without an MRI lesion, PML 
diagnosis cannot be verified. The sensitivity of MRI in identifying PML lesions has made it the modality of choice in monitoring 
natalizumab treated MS patients for early detection of PML.  Consideration of imaging in relation to the clinical stages of PML 
requires understanding the clinical manifestations that PML takes, depending on the degree of brain infection, as well as the status of 
immune response to this unique infection. (Table 2)  We define onset of PML as the time JC virus enters brain and infects 
oligodendrocytes, which ultimately leads to a clinical serious brain injury. Table 2 emphasizes that there is a pre-symptomatic period 
during which the infection grows which even by MRI is likely to be 3-6 months in duration.
62
 This accounts for some of the low risk 
of early months of therapy, as well as the interval when PML is most likely to be seen after stopping natalizumab and transitioning to 
a low risk therapy. The symptomatic disease state is very different depending on whether immune reconstitution is achieved or not. 
Without immune reconstitution, the “classic” PML is generally fatal, and no effective immune response is generated. Alternatively, as 
generally occurs in natalizumab cases, successful immune reconstitution precipitates an inflammatory syndrome that can arrest the 
disease.  This response must come quickly enough to avert death from disease progression, but when it occurs and the patient survives 
>6 months, the viral disease is generally controlled, albeit with a fixed brain lesion seen in post-PML survivors. (Table 2) PML 
therapy has been reviewed in detail elsewhere.
63
 No anti-viral therapies, including widely used mirtazapine and mefloquine
64
,  have 
been demonstrated to improve outcomes, but it is abundantly clear that immune reconstitution changes the course of PML for the 
better.  The concept of using plasma exchange to hasten immune reconstitution with natalizumab cases is thus a rational approach that 
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has been widely adopted and associated with PML outcomes that outpace historical precedents.
65
  However, the balance of concerns 
about potential augmentation of damaging IRIS remains a concern that clinicians must balance.
66,67
 Similarly, active use of 
corticosteroids or maraviroc
68
 to blunt IRIS remain controversial, but at least in more advanced disease active immune reconstitution 
seems likely to contribute to better outcomes. Gathering informative data to more clearly articulate recommendations remains 
extremely challenging with this rare and serious disease.  Urgency for early diagnosis of PML (Table 2, 3), preferably before the onset 
of clinical symptoms, aims at limiting brain damage and thus disability. Recommended MR parameters are widely available. 
Increasingly, annual scans including brain and spinal cord are recommended to monitor the efficacy of DMT for MS (Table 3).  Even 
more frequent scans of brain alone are recommended seeking early detection of PML in higher risk settings. Retrospective analysis of 
some PML patients with frequent scans demonstrates lesions developing months before symptoms.
62
 It is now recognized that 
development of PML symptoms may only occur months after JCV enters the brain and forms a visible lesion with MRI.  To date, we 
found 19 publications 
2,62,69-83
 reporting on 48 PML patients asymptomatic at the time of a detectable lesion. Twenty-one of these 
patients developed symptoms in up to 41 weeks after lesion visualization and in a further 13 patients natalizumab was withdrawn 
before the development of symptoms, with 4 patients remaining symptom free. Disabling outcomes including mortality appear to be 
reduced in these patients.
82
   
 It is critical to be aware that verified PML lesions actively evolve on repeated imaging, either because the JCV induced disease 
progresses, or because the inflammatory response controlling the infection results in evolution of the image characteristics. Thus, 
repeated MRI images that do not change help rule out PML, while evolving lesions are consistent with a PML diagnosis. PML may 
not be diagnosed on a single MRI without additional clinical and virological confirmation.  
Despite the increasing number of PML cases reported, the low frequency, sporadic appearance, and uncontrolled clinical 
market status of natalizumab distribution, make a prospective assessment of the sensitivity, specificity and accuracy of imaging 
difficult. It has been suggested that the 4 most helpful features suggesting a PML lesion (applicable to lesions in asymptomatic 





 (Figure  2)  Unlike AIDS associated PML, GD contrast enhancement is often seen even at presentation in 
PML in the setting of treated MS. Occasional cortical and deep GM involvement can occur but white matter distribution dominates 
PML.   
 The punctate lesions may offer some insight into the pathophysiology of PML, suggesting an inflammatory response in the 
lesion.  Recognition of this imaging pattern has emerged in settings where partial immune response to JC virus is commonly present, 
and was not noted in the era when most cases were AIDS associated and lacked inflammatory response on pathologic exam. Punctate 
lesions appear to develop in perivascular spaces in the brain, where JCV in mononuclear cells and infected glial cells has been 
identified.
25
  Histological examination has shown that inflammation typical of IRIS to JC virus is associated with a marked infiltration 
of CD8+ T lymphocytes, especially in the perivascular spaces.
85
 The frequent observation of this pattern thus may be a marker of 
IRIS, and is consistent with the early evidence of contrast enhancement suggesting IRIS in many natalizumab associated cases of 
PML. While punctate lesions often enhance with GD, their unenhanced presence on T1suggests pathology outside intrinsic brain cells 
supporting JCV replication, and thus may instead specifically reflect inflammatory response. The alternative interpretation that these 
are the smallest “islands” of demyelination in early infection is plausible, but their early enhancement favors their location in relation 
to blood vessels with increased permeability to GD. If these lesions reliably represent disease with IRIS, they could direct clinicians to 
focus on anti-inflammatory therapy for these patients. Another interesting MRI lesion similarly reflecting probable inflammatory 




Confirming the Diagnosis of Pre-symptomatic PML 
 The success of frequent MRI brain imaging will be measured by the identification of increased proportion of asymptomatic 
lesions determined to be PML. AAN Diagnostic Criteria
61
 require symptoms for definite diagnosis, yet ideally PML would be detected 
and arrested without symptomatic brain damage occurring through close MRI monitoring of high risk patients. Verification of a PML 
diagnosis without symptoms is challenging. Very early, CSF viral load may be low or undetectable and the dynamic nature of PML 
11 
 
cannot be confirmed by a single scan. MRI lesions may be characteristic of PML, but no MRI features have been described as being 
pathognomonic.  Small lesions can be difficult to differentiate from MS lesions especially when there is a high lesion load.
83
 
 A critical clinical point is that in patients at risk, new MRI lesions consistent with PML should be assumed to be PML, and 
active longitudinal diagnostic and therapeutic steps including repeated CSF sampling (if required), repeated MRI imaging, and serial 
JCV antibody titers should be performed to help establish the diagnosis. During these procedures clinical management should be 
pursued as if PML is present. Delay in managing PML by awaiting AAN definite diagnostic criteria, would sacrifice the benefits of 
early detection gained by monitoring with MRI. Such an approach was successfully implemented in at least 3 patients with PML 
compatible MRI changes but negative CSF JCV PCR.
69,71
 In these 3 patients managed as if the diagnosis was established, two had 
subsequent detection of JCV in CSF on repeat sampling. In all patients the MR imaging evolved to a pattern compatible with 
development of PML with IRIS, helping to strongly support the diagnosis. Often asymptomatic patients later develop symptoms 
associated with IRIS, ultimately fulfilling traditional diagnostic criteria. 
 To date, serial quantitative JCV antibody determinations have too rarely been used to help consideration of possible PML in 
difficult cases. Active JC virus disease including PML typically drives an increase in JCV antibody titers that confirms JCV related 
disease. Thus, even if viral DNA is not demonstrated in CSF, if compatible and evolving MRI lesions are associated with increasing 
systemic JCV antibody titers, this should provide significant support for diagnosis of PML.
87
 Use of this approach may not work in the 
face of prior immunotherapy, however, necessitating biopsy or presumptive diagnosis without confirmation. Brain biopsy remains the 
ultimate criteria when a definite diagnosis is required lacking detection of viral DNA in the CSF. However, with small pre-clinical 
lesions, it will be difficult to biopsy at the earliest stages, and should be only used judiciously when certainty about the diagnosis is 
clinically critical.  
 
 
Risk Mitigation Strategies Are Failing Us 
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 A risk mitigation strategy was developed by Biogen/Idec to protect patients from developing PML in the setting of 
natalizumab therapy.
88
  The fundamentals have been actively discussed, and variably applied. 
10,11,89-93
 However, the ideal of 
witnessing plummeting incidence of PML cases has not yet materialized. 
94
 We summarize our own suggestions based on a most 
recent algorithm 
95
 and the data we are aware of in Table 3. We propose the surveillance be guided by the estimated risk, 
dichotomizing it into 2 groups: a) regular surveillance if the PML risk is ≤ 0.9/1000 and b) intensive surveillance if it is above 
0.9/1000 patients. This approach allows simple adjustments when the estimated risks change or new risks are identified. (Insert: 
Recommendations)  
Shortcomings of risk stratification elements 
The substance of the three key risk stratification elements is known to have flaws that might help understand the suboptimal 
impact they exert. First, while JCV antibody is a predictor substantiating infection with the virus causing the disease. Unfortunately, 
JCV viremia and viruria can be present in antibody negative patients.
96
 Further, quantitative antibody analysis, while suggestive of 
more active infection with higher risk, fails to be predictive after prior immunotherapy. While overall expression of antibodies 
inversely correlates with disease risk, some evidence that antibodies still may play a role in controlling this virus is emerging, reviving 
interest in vaccination strategies for JC virus or PML management.
42,97
 Thus, JCV antibody status falls far short of an ideal biomarker. 
Second, duration of therapy as a risk parameter is also flawed.  The measured variable is duration of time from natalizumab therapy 
start to clinical diagnosis of PML, which itself may be a considerable time after the first symptoms.
98
  The actual biologic interval of 
interest is time to brain infection with the virus. Through observations with more intense monitoring of pre-symptomatic high risk 
populations, we now realize that infection likely takes place at least 6 months prior to the clinical manifestations of disease, 
substantiated by observation of pre-symptomatic lesions of PML on MRI scans, and by pre-symptomatic immunoglobulin elevations 
leading up to PML diagnosis.
29,82
 It is likely that the pre-symptomatic interval is even more variable related to the eloquence of 
clinical expression of lesions in different brain regions. For example, it seems likely that brainstem lesions would more rapidly lead to 
symptoms compared with frontal lobe lesions. Thus, extrapolation about specifics of pathophysiology based on the crude interval from 
13 
 
start of therapy to clinically symptomatic disease is quite imprecise. Recent critical analysis about the imprecision of the Biogen risk 
estimates for impact of duration of infection become even less meaningful, when the imprecision of biology reflected by the measure 
is considered more critically.
92
 Third and finally, the impact of prior immune suppression on risk is similarly quite poorly fleshed out 
in literature. It is fundamentally untenable that the specifics of type and duration of prior immunotherapy is of little consequence in 
determining risk on a biologic basis, yet this is at present a monolithic consideration. A dose of azathioprine would receive equal 
weight with long term cyclophosphamide therapy, yet impact on the immune system must be very different.  
Thus, current negative commentary on the precision of the present risk mitigation strategies is unsurprising, but perhaps 
clinically not so critical.10,92,99,100 
 
 
Risk stratification with newer disease modifying MS therapies 
The risk mitigation developed for natalizumab is likely only truly applicable in relation to that drug. PML risk with other 
available and emerging DMT for MS (dimethyl fumarate, fingolimod, rituximab, ocrelizumab) is much lower,
89
 and while its presence 
must be acknowledged, it should not severely impact decision making where benefits can be accrued by implementing early and 
effective MS therapy. In the case of dimethyl fumarate, monitoring for lymphopenia appears likely to identify a higher risk group in 
whom alternate therapy should be sought. In that setting prolonged lymphopenia with absolute lymphocyte counts <750 accounts for 
most cases, although the risk may reside particularly in the loss of CD8 cells critical to JCV control.
101
 Measurement of circulating 
lymphopenia however is not universally helpful. For fingolimod, this strategy cannot be applied since circulating lymphocytes decline 
while effective lymphocytic function appears largely normal.  Similarly, alemtuzumab associated risk for PML has not been 
demonstrated in MS patients yet despite marked impact on lymphocyte profiles. Alternatives to lymphocyte counts might include 
serial antibody measurements, or monitoring for circulating JC virus. The multiplex PCR that allows identification of emergence of 
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prototypic virus that likely has enhanced risk of PML seems a plausible means of risk stratification, but has not yet been demonstrated 
to serve in this way.
23
 However, the low overall risk with alternative DMT makes it difficult to validate, and probably impractical to 
use as a stratification factor in practice. Other alternative PML risk stratification approaches under investigation in natalizumab 
associated PML include measurements of CD62L and lipid-specific IgM bands. 
102,103
At present similar logic applies to rituximab and 
ocrelizumab. These monoclonal antibodies directed against B cells have yet to demonstrate excess risk of PML in MS patients despite 
a large number of cases associated with rituximab when used in the setting of hematologic malignancies and other diseases with 
greater underlying risk of PML.
104,105
 The theoretical risk suggests clinical vigilance, but no other risk mitigating strategy can be 
recommended for PML at this time when using these emerging MS therapies.  
Thoughts on risk mediation based on what has been learned 
Ongoing consideration of additional risk mitigating factors that would aid risk assessment and be more predictive should be a 
theme of investigation. Technology that allows more detailed consideration of JCV specific immune control might more accurately 
reflect risk. Quantitative definition of the specifics of T cell recognition and response, as well as identification of the emergence of 
prototypic virus might well alert the clinician to a small subset of high risk patients in whom therapy would be foolhardy.  
The fact that the present system has largely deluded us all is evidenced by the lack of impact so far on the incidence of new cases. 
While the imprecision of the present risk model is likely in part to blame, the most likely cause is that risk monitoring and 
communication is either too inconsistently done to inform patients, or that they are choosing to continue to use natalizumab even when 
they have a significantly elevated risk.  
Development of therapeutics for auto-immune diseases including MS, genetic origin of immune disorders or neoplastic disease is in 
evolution, and optimizing these choices to include PML risk will require more detailed data than currently exists. For example, the 
relative efficacy of MS therapies, as well as their costs must inform prescribing patterns. Estimates of these factors are difficult to 
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substantiate. These factors must be integrated with the risk of PML encumbered by various therapies. Calculation of all of these 
factors, and explaining them to a patient who must fit this evidence into a personal risk tolerance profile is a very difficult task. Better 
tools need to be developed to assist patients and physicians in meaningful ways to understand this and come to an ethically sound 
decision for the patient’s management.106 
 
 
Conclusion and future directions 
 The past decade has witnessed substantial progress in understanding JC virus and PML. The close observation and additional 
cases seen in multiple sclerosis patients has given the opportunity to enrich the molecular biology of JC virus, and to make some 
progress on likely evolution of risk and invasion of the brain. Enhanced identification of higher risk patients has allowed the evolution 
of use of MRI, such that detection of PML lesions prior to symptom onset is commonplace in high risk patients. Improved use and 
interpretation of MRI have proved pivotal for PML. However, the clinical management of MS patients remains challenging. 
Further, the outcomes from PML have markedly improved. While PML is still a serious and sometimes lethal disease, a majority of 
patients contracting it survive in settings where immune reconstitution is possible, and with early detection of disease, commonly 
severe disability from PML can be avoided. However, we still are unable to detect individual risk precisely enough to give easy 
instructions about PML, and still settle for very early diagnosis to minimize injury.   
Meanwhile, the practical means to enhance communication about risk and help patients select the optimal approach to their illness 
tailored by their own willingness to take risk is an ongoing clinical challenge. It is especially important to be sure that it is not for lack 
of monitoring and acceptance of known risk that patients are developing PML. If on the other hand, patients have accepted the risks 
and continued therapy with full knowledge of risks and benefits, principles of ethical care have been served. Ultimately understanding 
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the overall difference in outcomes of those who accept the risk with DMT and do well, compared to those who develop PML, should 
be understood and have acceptable value,  if the choice to use this therapy is to continue to be up to patients and their clinicians.  
The basis for such an analysis is the availability of credible data. PML is not a reportable disease, and detailed retrospective data 
gathering is laborious and incomplete. Registration of cases with systematic reporting of circumstances of the disease would allow us 
to study the impact of risk mitigation concepts. Development of widespread or universal data collection and consideration of cases 
could speed research on risk and outcomes, and allow more precise risk mitigation programs. We believe that while the mitigation 
strategies are not perfect, the largest failure is in not implementing changes in therapy when risk is known to be elevated. With MS 
therapies that are comparably effective to natalizumab, we believe replacement of natalizumab in high risk patients should be more 








Table 1 – Stages of JCV Infection Leading to PML 
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TABLE 1: Urinea Bloodb CSFc 
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Footnotes for Table 1 
a. Urine samples can be tested for JCV DNA to demonstrate a latent or persistent infection.   Approximately 30% or more of the population 
globally excrete JC Virus in the urine, viruria, without pathological effects in the kidney although very high levels of viral DNA can be present. The 
JCV archetype variant, unique arrangement of non-repeating nucleotide sequences in the non-coding control region or NCCR, is the most 
common in the urine. The JCV archetype variant is thought not to be neurotropic and is rarely detected in brain or CSF of PML patients.   
 
b.Blood samples are tested for antibody to JCV in either serum or plasma indicating prior exposure to JCV. Seroepidemiology of JCV has shown a 
global presence of JC Virus infection. However, multiple alterations throughout the genome can be found that have used to ‘Type’ JCV allowing 
studies to define geographical distribution and follow transmission in family members.  High levels of antibody or increasing levels of antibody, 
reported as a titer or index, usually indicate active infection from reactivation of latency or a new infectious episode. Antibody levels also may 
fluctuate so sero-positive or sero-negative status may change over time. Estimates that this conversion takes place in 2% to greater than 10% of 
the population annually. Also, rare seronegative individuals may experience JCV infection and not show or make antibody as evidenced by viruia 
or viremia.43   
Blood samples are also used to test cell compartments for JCV DNA as cell carriers for infection or persistence. Notably viral DNA has been found 
in CD19+/20+, CD34+ cells but not in CD 3 (T cells) or monocytes. 21 
c. CSF samples with detectable JCV DNA serve as the laboratory confirmation of PML diagnosis.   Quantification of viral DNA is reported as 
genome copies per ml.  Currently, the most sensitive assay has a limit of detection of 10 c/ml.23  Usually, the lower the copy number of viral DNA 
the better the PML prognosis.  Viral DNA in the CSF is the prototype variant with repeat nucleotide sequences in the NCCR thought to be derived 
from the archetype variant through deletion, duplication and rearrangement. This transformation from the archetype to prototype probably 
takes place before entry into the brain in lymphoid tissues like nodes or bone marrow.52,53 There can be multiple nucleotide arrangements of the 
NCCR in PML patients plasma, brain and CSF. However, generally no two PML patients demonstrate identical patterns although the same variant 
is found throughout an individual PML patient’s tissues. 41 
CSF samples also can be tested for intrathecal antibody to JCV that occurs in PML patients and may be used as a marker or sign of developing 
PML.43   
d. Antibody is measured by ELISA assay using viral major capsid protein, VP1 derived from the prototype variant, as antigen; result reported as 
titer 33or index34, depending on assay, reflecting the level of antibody response, usually IgG. Other VP1 variants have been reported that may 
have escaped immune control with mutations in the VP1 sequences that were identified in the CSF of PML patients with specific T cell responses 
so attributed as the potential PML causative variant.40 However, almost all PML patients with ELISA demonstrated antibody to JCV have the 
prototype variant in brain and CSF.    
21 
 
e. Viral DNA is measured using quantitative polymerase chain reaction specifically measuring copy number of viral genome DNA as c/ml;  
low=50c/ml; hi=>500c/ml. In MS/PML patients, the median c/ml is >100c/ml to <500 c/ml in a range of 10c/ml to 107c/ml 37  Primary infection is 






Table 2: Stages of Progressive Multifocal Leukoencephalopathy 
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No CE, Brain 
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mo after dx, then is 
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T1 cortex 
        
 
1 Duration of pre-symptomatic stage dependent on location in brain. Clinically silent regions like frontal lobes may harbor pre-symptomatic 
infection for up to 41 wks in one documented case, while areas causing symptoms with small lesions will be detected in fewer months. Duration 
of this phase is consistent with symptomatic PML occurring up in the first 6 months after natalizumab discontinuation. 
 
2Four most helpful features suggesting a PML lesion in asymptomatic patients: subcortical location (involvement of U-fibers), T1 hypointensity, 
DW hyperintensity, and the presence of punctate T2-hyperintense lesions. Evolution of lesion on subsequent scans important to substantiating 
diagnosis.  
 
3 Typical of PML developing in untreated HIV/AIDS or highly immune deficient setting where virutally no immune response seen. Classically this 
symptomatic disease led to death within 6 months in most patients.  
 
4 PML with IRIS can also occur at the pre-symptomatic and symptomatic phase where partial immune deficiency occurs (common in natalizumab 
MS at onset); punctate lesions (± CE) and T1 cortical bands probably indicate inflammation with or without CE. Prior cortiocsteroids reduce 
chance of CE without eliminating inflammatory response.  CE: Contrast enhancement 
 
5 PML with IRIS persists for up to 5 months or longer documented by late biopsy of lesions, and may require repeated therapy to suppress.  
 
6 Deaths from PML typically occur within 6 months of diagnosis, with survivors dying of other causes months to many years later, often hastened 
by underlying diseases, or the hazard of neurological disability and its complications.  
 
7 JCV DNA typically declines and often is undetectable after survival of PML. However, virologic cure does not occur, and CSF may continue to 










Table 3:  Protocol for PML surveillance in MS patients 
  
Monitoring steps for Patients  MRI Sequences 
  
Treatment Group PML risk S Anti JCV 
AB 









    FLAIR T2 DWI T1 T1+Gd PD/T2/STIR T1+Gd 
   
Immunmodulatory 
treatment  
    Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
All NTZ patients     Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
 Anti JCV negative NA NA  6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 




   
 Index <0.9 1 – 72M 0.1 – 0.6 R 6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
Index 0.9-1.5 1 – 36M 0.1 - 0.8 R 6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
37 – 72M 2 - 3 I  3-4 M PML Y6 Y7 Y - - - - 
Index >1.5 1 – 24M 0.2 – 0.9 R  Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
25 – 72M 3 - 10 I  3-4 M PML Y6 Y7 Y - - - - 
JCV +ve, Previous 
Immuno-
suppression 
1-24M 0.3 - 0.4 R  Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 




Abbreviations:  FLAIR = fluid-attenuated inversion recovery, DWI = diffusion weighted imaging, I = intensive surveillance, S = surveillance, 
T1   T1 + Gadolinium,  PD = proton density  , STIR = Short T1 inversion recovery; NTZ= Natalizumab, R = regular surveillance 
a Risk estimates from report of EMA, February 2016107 
MS: Monitor MS activity, justified by aim to provide DMT achieving “no evidence of active disease” (NEAD) for optimal clinical 
management of MS 
PML: PML Surveillance 
1Spine MRI is not indicated for PML monitoring, but may be used in monitoring MS disease activity, or if neurological exam suggests 
possible spinal cord localization of pathology 
2Rovira108:  Mandatory  a) Axial proton-density and/or T2-FLAIR/T2-w; b) 2D or 3D contrast-enhanced T1-w 
Optional a) Unenhanced 2D or high-resolution isotropic 3D T1w; b) 2D and/or 3D dual inversion recovery;   
    c) Axial DWI 
3Traboulsee109: Mandatory (Core)  a) Anatomic 3D inversion recovery–prepared T1 gradient echo Gd;   b) 3D sagittal T2WI FLAIR;   c) 3D 
T2WI;    d) 2D axial DWI;   e) 3D FLASH (non-IR prep) postGd 
Optional:  a) Axial proton attenuation;    b) Pre- or post Gd axial T1 spin-echo;    c) SWI 
4 Optional in Rovira et al and mandatory in Traboulsee et al 
5 Optional in Rovira et al 
6McGuigan95 et al and Traboulsee et al recommend FLAIR 
7Yousry83 et al recommend FLAIR or T2-w; there is no data suggesting superiority of one sequence over the other in this specific scenario 
8Spine Traboulsee et al  Mandatory a) Sagittal T2; b) Sagittal PD, c) STIR, or PST1-IR; d) Axial  T2 through lesions 
     Optional a) Axial T2 through complete cervical cord; Gd & post-Gd sagittal T1 
Rovira et al    Mandatory a) Dual-echo (PD and T2-w); b) SE and/or fast SE; c) STIR (as an alternative to PD-w); d) Gd T1-
w SE (if T2 lesions present)    
     Optional  a) Phase-sensitive inversion recovery (as an alternative to STIR at the cervical segment) 
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       Axial: a) 2D and/or 3D T2-w fast SE; b)GD T1-w SE 
 
















































Figure 1: Stages of PML pathogenesis 
 
1. Initial infection through ingestion and/or inhalation of virion particles may lead to subacute infection and stimulation of antiviral 
antibody. No formal study has been conducted however to document these events. 
 
2. In some individuals, approximately 30% globally, JCV infects the uroepithelium of the kidney and establishes a persistent or latent 
infection as evidenced by excretion into the urine with little if any pathological consequences.  
 
3.  JCV may escape into the peripheral circulation in some individuals and spread virions into lymphoid tissues including bone marrow 
establishing a latent infection that can be reactivated at times of immune suppression or modulation. 
 
4. CD34+ cells in the bone marrow can become infected.  Natalizumab forces consistent migration of CD 34+ cells to the peripheral 
circulation that continues for years during treatment. 
 
5. Some of the migrated CD 34+ cells differentiate in a lymphocyte pathway, predominately in B cell lineage. Some of these cells that 
may be latently infected use these cells as host for viral multiplication.  
 
6. Both DNA transcription factors like SpiB in the POU2A domain as well as miRNAs are temporally regulated by natalizumab and favor 
JCV multiplication in latently infected cells. Viral genome may undergo nucleotide rearrangement in the non-coding regulatory 
region from the urine associated archetype, less pathogenic form to the prototype, PML associated pathogenic form      
 
7. JCV multiplication takes place in these cell phenotypes that may be recognized by CD4 and CD8 immune clearance as well as 
contributions of anti JCV antibody. Some infected cells escape immune clearance. 
 
8. JCV can remain in circulating B cells, perhaps pre B cells, as well as non-cell associated, free virions in the circulation and traffic to 
the brain.  
 
9. JCV can enter the brain in infected cells or free virus via hematogenous routes and initiate infection in the target oligodendrocyte. 




10. PML initiates as virus begins lytic, necrotic oligodendrocyte infection with gradual spreading of virus as evidenced by growing lesions 
in a multifocal pattern. a)represents MS lesions in PML patients treated with natalizumab; b)cortical white matter lesions with 
punctate lesions just below that are typical in PML and c)PML lesions in U fibers near the cortex. 
 
 
Figure 2:   
Natalizumab associated PML in an MS patient A, C, E: FLAIR images; B, D, F: Enhanced T1w images 
Asymptomatic PML (A and B): Enhancing right frontal lesion with multiple smaller non enhancing punctate lesions (white arrow) 
PML and IRIS (C and D): The lesion has enlarged on FLAIR and the enhancing area has increased; note the enhancing punctate 
lesions bilaterally (white arrows) 








 Risk biomarkers for PML must be expanded and made more accurate 
 Enhanced global data collection on cases of PML should be pursued to inform risk assessment and outcome analysis 
 Recommendations for surveillance should be geared to risk profile 
 Lower risk patients(<0.9 cases of PML/1000 exposed)  should receive routine assessment for MS disease activity as part of 
disease modifying therapy selection and refinement as well as PML surveillance 
 Higher risk patients (>0.9 cases of PML/1000 exposed) should undergo enhanced PML monitoring with more frequent MRI 
and antibody index assessments 
 Updated risk assessments should be available as output from the surveillance network allowing best practices refinement of 
practice 
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A decade of lessons learned: PML pathogenesis and risks associated with therapies for MS  
 
Introduction 
Over one decade has passed since the first report of progressive multifocal leukoencephalopathy (PML) in several MS multiple 
sclerosis (MS) patients receiving natalizumab in a clinical trial. This monoclonal antibody to α4 integrins blocks inflammatory cells 
entry into the brain and blocked MS related clinical relapses. The occurrence of two very different demyelinating diseases in the brain 
of a single patient was unanticipated since PML and MS have very little in common except the destruction of myelin.  The etiology of 
PML is a viral induced lytic brain infection while the main etiology of relapsing/remitting MS remains anis an autoimmune response. 
PML in these MS patients was quickly associated with natalizumab, primarily because MS patients had been treated with other 
immune therapies for decades without reports of PML.
1-4
 The link between natalizumab treatment in MS patients and PML, however, 
was further confirmed as more cases of PML were identified. Subsequently, tThere have been several recent  rare reports of PML in 
MS patients on other therapies like dimethyl fumarates and fingolimod. but those numbers are very few.
5-9
 The initial incidence of 
PML in natalizumab treated MS patients in the phase 3 trial was estimated to be 1 in 1000.
4
 Ten years later, >75000 PML cases have 
been reported with >20% fatality rate, and substantial morbidity to survivors. (Biogen, Tysabri Safety Update, September 2017, 
https://medinfo.biogen.com/secure/pmlresource)   and tThe incidence in patients on long term>24 months treatment, and antibody 
evidence of JC Virus (JCV) exposure, and prior immunosuppressant treatment has reached at least 1 in 70, an incidence much higher 
than any other opportunistic infection in this setting.,
10,11
 Use of a more quantitative antibody index has recently yielded estimates of 
2.7% after 72 months natalizumab therapy with prior immunosuppressant exposure.
12
  The incidence of PML in MS patients on other 
immune modulating therapies is much less, perhaps 1 in 10,000 to 1 in 100,000. So what have we learned from this experience on the 
pathogenesis of PML and how might that knowledge be applied to distinguishing therapy associated risks of PML that would help 
establish evidenced based monitoring of patients and inform the selection of effective MS treatments for individual patients?  There 
*Manuscript with revisions highlighted
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are several areas that surfaced from investigations on PML in MS patients that will be explored in this review: 1. Tthe molecular 
aspects of pathogenesis and cell specific involvement of JCV infection leading to PML, that are generally applicable to all PML cases 
regardless of various underlying diseases.  that may be generally applicable but also that specifically relate to unique physiological 
effects of natalizumab; 2. the central role of magnetic resonance imaging (MRI) in the diagnosis of PML, monitoring treated patients 
to control its morbidity and advancing our understanding of aspects of its pathophysiology, and 3. new insights of clinical value of 
early PML detection. These are three areas in which progress has been made on both PML and also MS disease pathogenesis.  
 
JC Virus infection and PML pathogenesis 
To understand the complexities of the pathogenesis of PML, it is important to detail some of the background and biology of JCV 
infection leading to PML. First described in 1958, PML is usually characterized as a rare disease caused by JC Virus, named from the 
initials of the first patient from whom the virus was isolated in 1971.
13
  PML develops in patients with compromised immune systems, 
particularly cell mediated immune responses. However, there have been a small number of PML cases with no identified evidence of 
immune dysfunction. Until the mid 1980s, PML was reported in patients with underlying neoplastic diseases, mostly 
lymphoproliferative diseases, and a few organ transplant patients treated with immune suppression for graft protection.
14
 In the mid- 
1980s, HIV-1 infection became the predominate risk with up to 5% of AIDS deaths associated with PML. Effective antiretroviral 
therapy and earlier initiation to avert severe immunodeficiency have decreased the risk in HIV infected patients with an approximate 
incidence of to <1%  . 
15,16
 Using a Pubmed search in 2017, we found that since 2005, reports of PML in patients with MS and other 
underlying diseases, and therapies to treat them, have increased 10 fold suggesting a greater awareness of PML based on clinical 
evaluation, MRI imaging and use of laboratory tests for JCV DNA and anti JCV antibody. It may be time now to consider PML not as 
just a rare disease but as a substantial neurological complication in certain high risk populations.   
Comment [c1]:  
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The pathophysiology of JCV in human hosts leading to PML is outlined in Figure 1 following steps 1 through 10 with additional 
details in Table 1, and further annotateded in Table 1. JCV has a narrow cellular host range and a variable effect on the organs it 
infects. Infection in human endothelial cells in the kidney
17-20
 and in cells of hematopoietic lineage like CD34+, B cell phenotypes, 
CD19+ and CD20+ have little  pathological effect making infection of hosts a silent event. 
21
  In the brain however, the multiplication 
in oligodendrocytes is lytic and results in PML with devastating clinical consequencsconsequences. Infection of the neurons in 
granular cell layer in the cerebellum can also result in a symptomatic neuronopathy. 
22
 
For cells to be susceptible to JCV infection, they need to express DNA binding proteins that recognize the viral genome, non-coding 
control region (NCCR) that initiates viral DNA replication and transcription for RNA and eventually protein synthesis (Figure 1steps 
6,7/Table 1). There are a number of such transcription factors that are critical to JCV multiplication. 
23
 The noncoding control region 
(NCCR) nucleotide sequences are represented in two arrangements. The archetype NCCR is comprised of approximately 200 linear 
nucleotides in virions excreted in the urine, figure 1,step 2,which occurs in about 30% of the population. This ‘archetype’ variant is 
generally considered non-pathogenic in kidney or, if identified, in other compartments like plasma/serum and even in brain. Virus 
isolated from PML patient’s brain, like the index patient JC, became known as the prototype variant associated with pathogenic PML 
brain and CSF.
23
 These approximately 200 NCCR nucleotides are not arranged linearly but in direct tandem repeats of 98 nucleotide 
base pairs or other arrangements but always showing duplications. It is thought that the prototype variant is derived from the archetype 
by deletion and duplication. The tissue compartment or cell type in which a ‘rearrangement’ of the NCCR from archetype to prototype 
could take place is still not known but lymphoid cells are a very probable host. (Fig 1, steps 4,5),
24-27
 While there are no specific 
studies in cell culture or in patients that show that such a rearrangement can take place, there are very compelling indirect data 
supporting such a mechanism. New evidence even implicates Epstein Barr virus coinfection as possible catalyst in the nucleotide 





Sero-epidemiological studies show a global distribution of JCV with an estimated rate greater than 50% of the adult population having 
been exposed. 
29
The initial site of infection is still not known but thought to be ingestion or perhaps respiratory inhalation. (Figure 1, 
step1,) Contact with JCV most commonly results in a subclinical infection during which individuals develop antibodies and cell 
mediated immune responses (Table 1).
30,31
 The serology test used for these studies had been hemagglutination inhibition( HI) based on 
the virions’ ability to aggregate human type O erythrocytes. Anti JCV antibody would inhibit that reaction. Using this assay, a recent 







 This observation has been verified with the development of ELISA assays that use recombinant produced VP-1 
and not whole virions.
33
  VP-1 is the major capsid protein making the outer structure of the viral icosahedral particle and functions in 
cell attachment. The commercial Quest Diagnostic assay, Stratify
TM




 uses the 
same VP-1 produced by recombinant technology.
34
 Based on these assays, approximately 55% of MS patients are JCV seropositive. 
There are patients who ‘seroconvert’ from negative to positive at a higher rate than those who ‘serorevert’.  The rates of 
seroconversion in either direction may range from 3% to as high as 10% over a course of years.
35
 This observation can complicate 
testing for anti JCV antibody as part of a risk mitigation program for PML since presence of antibody indicates prior viral infection. 
An increase in antibody titer or index indicates a history ofn active infection resulting from a persistent or reactivation of latent 
infection. An algorithm using the antibody index, calculated using the optical density in the Stratify ELISA assay, shows a correlation 
with PML risk.
36
 A substantial rise in antibody has been identified in PML patients both in their plasma and CSF for weeks or months 
after diagnosis.
37
 There are also reports of an increase in antibody to JCV in natalizumab treated MS patients that is most likely due to 
release of a previous latent or persistent JCV infection with a subsequent antibody response. The value of regular intervals of anti JCV 
antibody monitoring is important but should be put into context. The antibody results indicate whether a patient has been exposed and 
if titers/index increases substantially may indicate that an active infection has taken place. However, reliance on antibody titers/index 
change is limited as illustrated by the apparent absence of increased titers in patients with prior immunosuppression. However, 
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fundamental virology principles across most viruses that can become latent accept that individuals who have been exposed to a virus 
are at greater risk for disease from that virus than those who have not been.   
In addition, anti JCV antibodies may be directed to different regions of the primary capsid protein, VP-1, that could be unique to a 
particular patient. As is the situation with the viral NCCR, the VP-1 gene can be hypervariable producing a number of VP-1 proteins 
with different primary amino acid sequences compared with the prototype variant. This has been known for many years in the 
thorough description of the ‘JCV Type’ linking geographical locations with independent V P -1 genes and protein variants.38  So it is 
not surprising that any one PML patient may have multiple representations of VP-1 protein at any one time. This observation had led 
to the hypothesis of VP-1 gene rearrangement that could result in a more ‘neurovirulent’ variant leading to PML.39,40 This observation 
warrants further investigation that would require ‘deep sequencing’ studies.41 However, it appears that PML patients are infected with 
the prototype VP-1 protein since that is the antigen used in the ELISA assays of commercial, academic and government laboratories. It 
is possible that immune escape of JCV VP-1 variants could occur due to either persistent JCV in cell compartments or mutations in the 
VP-1 gene to avoid immune recognition.
40
 This has been an area of new investigation in the last several years.  
Although However, antibodiesy to JCV may not likely result in protection against PML development (and are thus not necessarily 
neutralizing antibodies)., There is ample in vitro data showing antibody made against JCV blocks virion adsorption to target cells that 
limits attachment and entry, thus reducing viral multiplication.  But there is little clinical evidence in healthy people or patients 
showing antibody may help control JCV infection.
42
 In fact nearly all individuals who persistently shed JCV in their urine are 
seropositive. Some seropositive individuals can even be viremic, and PML patients can have very high levels of CSF antibody in the 
presence of high viral DNA copy numbers.
43,44
 Consequently, CD 4+ and CD8+ cytotoxic cell recognition of viral antigens probably 
play a pivotal more significant role against JCV infection. CD8+ cytotoxic T cells to JCV prototype VP-1 have been identified in PML 
and non-PML patients for many years.
45,46
, (Fig 1,step7) With the increase reported incidence of PML in MS patients treated with 
DMTs, newer studies have identified CD 4+ T cells as critical to control of JCV in natalizumab treated patients directed against the 4 
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major JCV proteins, T antigen, VP-1, VP-2, and agno. In addition, lack of CD 4+ cells and those releasing Il-10 were identified in 
natalizumab treated MS patients including one of the index cases who remained persistently JCV positive in CSF for years. 
47
 CD 4+ 
T cells have also been cultured from brain tissue of PML patients that are directed to potential more neurotropic viral capsid proteins 
not identified by CD 4+ T cells in the periphery. These CD 4+ cells seemed necessary to stimulate cytotoxic CD8+ cells to function 
for clearance of JCV from the brain so perhaps were lacking in PML patients.  These laboratory and clinical studies have been 
undertaken directly in response to the need for a better understanding of the immune system role because of PML incidence in MS 
patients. Perhaps in further defining risk factors for PML, identifying CD 4+, CD8+ and other immune system cells for activity to JCV 
antigens would be informative in the PML high risk patients.  
Unlike MS, the specific etiologic cause of PML is well known, JC Virus lytic infection of oligodendrocytes. To acquire a deeper 
understanding of the pathogenesis of PML, there needs to be a magnified focus on the virus including the stages of infection leading to 
oligodendrocyte cell death. (Figure 1, step 10) 
A case can be made that common pathophysiologic pathways explain the steps leading to PML, regardless of the underlying risk that 
allowed it. For example, some patients with T cell immune compromised systems may harbor JCV in a latent state in tissues like 
kidney, lymphoid organs like bone marrow, and possibly brain. Periodic JCV release from latency or even a persistent infection is 
poorly managed by the immune system so virus may enter the brain as free virions or through an infected cell (Figure 1, step 9/Table 
1). CD 4+ cells that do not adequately recognize JCV antigens have now become an important part of lack of immune surveillance
48
 
while cells in the B cell lineage have been implicated as possible carriers since JCV has been identified in CD 19 and CD 20 cells.
49
 
The brain is not the initial site of JCV infection and data on latency in brain are very limited. and not described in MS patients. There 
have been reports of identification of JCV DNA in brain tissues of non-PML patients.
50
 In these reports, there was no evidence that the 
entire viral genome was present in order to initiate and sustain viral multiplication.   In fact tThere is only one study that specifically 
investigated the presence of JCV DNA in MS brain tissue and did not find any evidencefound it absent. 
51
 A multicenter study using 
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blinded samples and controls of positive and negative brain tissues should be considered to determine the existence of latent JCV in 
the brain. However, at this point it is more It is likely that release of latent JCV in the periphery, particularly the virulent variant, is a 
key factor. The kidney/urine derived variant is considered non-virulent or at least less neurotropic, so the best candidate for latency is 
likely in lymphoid cells (Fig 1, step 4,5,Table 1). 
52
These cells can be hosts for rearrangement of the viral NCCR and perhaps gene 
rearrangement of the VP-1. They would be subject to factors that activate viruses like EBV that may even assist in JCV NCCR 
rearrangement from the archetype to the prototype by gene rearrangement and insertion as well as the potential to be targets for RAG 
1 and RAG2 enzymatic mechanisms best known for their role in immunogloblulin diversity.
53,54
  
So a question becomes what unique features does natalizumab possess that no other therapy associated PML risk shares. Natalizumab 
associated PML patients are not systemically immune suppressed. Other opportunistic infections are not prominent, suggesting PML 
is a specifically enhanced problem rather than the result of broad immunosuppression. Further, it appears to require years for the risk 
to be manifest. These two factors highlight the need to understand PML pathogenesis beyond pure immune suppressive explanations. 
It may be over simplistic to suggest that lack of immune surveillance is the major underlying mechanism of PML in natalizumab 
treated MS patients. Even with immune reconstitution inflammatory syndrome (IRIS), some natalizumab treated PML patients 
continue to have detectable virus in CSF for months to years. 
37
 We see two unique features of natalizumab that contribute to its 
special risk. One is that natalizumab forces migration of hematopioietic stem cells, CD34+ and precursors of B cells from the bone 
marrow (Figure 1, step 4). It shares this feature with efalizumab, the other monoclonal with highest risk of PML. The other is the 
temporal relationship of PML incidence after long term dosing, approximately 2 years or longer.  JCV can be latent/persistent in CD 
34+ or preB cells in the bone marrow described by several laboratories
24,25,55
 and in culture models identifying DNA binding factors 
that act on the JCV transcription sites.
56
  These factors can also be found in CD 19 and CD 20 cells in the peripheral circulation. It is 
possible that the high percent of such cells forced out of the bone marrow for long periods would result in release of some latently 
infected cells (Figure 1, step 5). In those individuals, perhaps their immune system cells do not completely clear newly released 
virions particularly if remaining intracellular like EBV. But that observation does not account for the temporal correlation of the high 
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incidence of PML after nearly 2 years of dosing. However, natalizumab also upregulates genes in a critical pathway for maturation of 
B cells, POU domain DNA transcription factors particularly Spi B that binds JCV NCCR. The time course of natalizumab effect on 
POU domain regulation is consistent with PML incidence. 
57,58
 The two characteristics only occurring in natalizumab, forced 
migration of cells from the bone marrow and temporal upregulation of factors that highly favor JCV growth match the current 
observations of  delayed PML incidence and focuses attention on the cause of PML, JC Virus cellular interactions leading to PML 
(Table 1, steps 5,6). While perhaps still premature, it is noteworthy to consider how laboratory analysis of these factors in immune 





      
 
MRI Imaging for Early PML Detection/Diagnosis/Management 
 The approach to diagnosis of PML has been reviewed elsewhere, but routinely requires identification of active CNS pathology 
and JC virus in the brain.
61
  Brain imaging is a critical contributor to the diagnosis of PML.
61
 Indeed, without an MRI lesion, PML 
diagnosis cannot be verified. The sensitivity of MRI in identifying PML lesions has made it the modality of choice in monitoring 
natalizumab treated MS patients for early detection of PML.  Consideration of imaging in relation to the clinical stages of PML 
requires understanding the clinical manifestations that PML takes, depending on the degree of brain infection, as well as the status of 
immune response to this unique infection. (Table 2)  We define onset of PML as the time JC virus enters brain and infectsactive brain 
infection of oligodendrocytes by JCV, which predictably ultimately leads to a clinical serious brain injury. Table 2 emphasizes that 
there is a pre-symptomatic period during which the infection grows which even bmy MRI is likely to be 3-6 months in duration.
62
 This 
accounts for some of the low risk of early months of risktherapy, as well as the interval when PML is most likely to be seen after 
stopping natalizumab and transitioning to a low risk therapy. The symptomatic disease state is very different depending on whether 
immune reconstitution is achieved or not. TheWithout therapyimmune reconstitution, the “classic” PMLdisease is generally fatal, and 
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no effective immune response is generated.  With Alternatively, as generally occurs in natalizumab cases, successful immune 
reconstitution (generally guided by therapy, but occasionally spontaneous), an iprecipitates an inflammatory change occurs in PML 
lesionssyndrome that can arrest the disease.  This response must come quickly enough to avert death from disease progression, but 
when it occurs and the patient survives >6 months, the clinical viral disease is generally controlled, albeit with a fixed brain lesion 
seen in post-PML survivors. (Table 2) PML therapy has been reviewed in detail elsewhere.
63
 No anti-viral therapies, including widely 
used mirtazapine and mefloquine
64
,  have been demonstrated to improve outcomes, but it is abundantly clear that immune 
reconstitution changes the course of PML for the better.  The concept of using plasma exchange to hasten immune reconstitution with 
natalizumab cases is thus a rational approach that has been widely adopted and associated with PML outcomes that outpace historical 
precedents.
65
  However, the balance of concerns about potential augmentation of damaging IRIS remains a concern that clinicians 
must balance.
66,67
 Similarly, active use of corticosteroids or maraviroc
68
 to blunt IRIS remain controversial, but at least in more 
advanced disease active immune reconstitution seems likely to contribute to better outcomes. Gathering informative data to more 
clearly articulate recommendations remains extremely challenging with this rare and serious disease.  Urgency for early diagnosis of 
PML (Table 2, 3), preferably before the onset of clinical symptoms, aims at limiting brain damage and thus disability. Recommended 
MR parameters are widely available. Increasingly, annual scans including brain and spinal cord are recommended to monitor the 
efficacy of DMT for MS (Table 3).  Even more frequent scans of brain alone are recommended seeking early detection of PML in 
higher risk settings. Retrospective analysis of some PML patients with frequent scans demonstrates lesions developing months before 
symptoms.
62
 It is now recognized that development of PML symptoms may only occur months after JCV enters the brain and forms a 
visible lesion with MRI.  Reversal of enabling factors (like natalizumab) before any symptoms develop is thought to limit brain injury. 
To date, we found 19 publications 
2,62,69-83
 reporting on 48 PML patients asymptomatic at the time of a detectable lesion. Twenty-one 
of these patients developed symptoms in up to 41 weeks after lesion visualization and in a further 13 patients natalizumab was 
withdrawn before the development of symptoms, with 4 patients remaining symptom free. Disabling outcomes including mortality 
appear to be reduced in these patients.
82
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 It is critical to be aware that verified PML lesions actively evolve on repeated imaging, either because the JCV induced disease 
progresses, or because the inflammatory response controlling the infection results in evolution of the image characteristics. Thus, 
repeated MRI images that do not change help rule out PML, while evolving lesions are consistent with a PML diagnosis. PML may 
not be diagnosed on a single MRI without additional clinical and virological confirmation.  
Despite the increasing number of PML cases reported, the low frequency, sporadic appearance, and uncontrolled clinical 
market status of natalizumab distribution, make a prospective assessment of the sensitivity, specificity and accuracy of imaging 
difficult. It has been suggested that the 4 most helpful features suggesting a PML lesion (applicable to lesions in asymptomatic 
patients) are its subcortical location (involvement of U-fibers), T1 hypointensity, DW hyperintensity, and the presence of punctate T2-
hyperintense lesions.
80,84
 (Figure  2)  Unlike AIDS associated PML, GDd(Gd) contrast enhancement is often seen even at presentation 
in PML in the setting of treated MS. Occasional cortical and deep GM involvement can occur but white matter distribution dominates 
PML.   
 The punctate lesions may offer some insight into the pathophysiology of PML, suggesting an inflammatory response in the 
lesion.  Recognition of this imaging pattern has emerged in settings where partial immune response to JC virus is commonly present, 
and was not noted in the era when most cases were AIDS associated and lacked inflammatory response on pathologic exam. Punctate 
lesions appear to develop in perivascular spaces in the brain, where JCV in mononuclear cells and infected glial cells has been 
identified.
25
  Histological examination has shown that inflammation typical of immune reconstitution inflammatory syndrome (IRIS) 
to JC virus is associated with a marked infiltration of CD8+ T lymphocytes, especially in the perivascular spaces.
85
 The frequent 
observation of this pattern thus may be a marker of IRIS, and is consistent with the early evidence of contrast enhancement suggesting 
IRIS in many natalizumab associated cases of PML. While punctate lesions often enhance with GD, their unenhanced presence on 
T1suggests pathology outside intrinsic brain cells supporting JCV replication, and thus may instead specifically reflects inflammatory 
response. The alternative interpretation that these are the smallest “islands” of demyelination in early infection is plausible, but their 
early enhancement favors their location in relation to blood vessels with increased permeability to GDd. If these lesions reliably 
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represent disease with IRIS, they could direct clinicians to focus on anti-inflammatory therapy for these patients. Another interesting 
MRI lesion similarly reflecting probable inflammatory responses is a T1 bright subcortical lesion that is often associated with seizures 




Confirming the Diagnosis of Asymptomatic Pre-symptomatic PML 
 The success of frequent MRI brain imaging will be measured by the identification of increased proportion of asymptomatic 
lesions determined to be PML. AAN Diagnostic Criteria
61
 require symptoms for definite diagnosis, yet ideally PML would be detected 
and arrested without symptomatic brain damage occurring through close MRI monitoring of high risk patients. Verification of a PML 
diagnosis without symptoms is challenging. Very early, CSF viral load may be low or undetectable and the dynamic nature of PML 
cannot be confirmed by a single scan. Nonspecific white matter lesions are common, and in MS patients lesions may be part of the 
underlying disease. While MRI lesions may be characteristic of PML, but no MRI features have been described as being 
pathognomonic.  Small lesions can be difficult to differentiate from MS lesions especially when there is a high lesion load.
83
 
 A critical clinical point is that in patients at risk, new MRI lesions consistent with PML should be assumed to be PML, and 
active longitudinal diagnostic and therapeutic steps including repeated CSF sampling (if required), repeated MRI imaging, and serial 
JCV antibody titers should be performed to help establish the diagnosis. During these procedures clinical management should be 
pursued as if PML is present. Delay in managing PML by awaiting AAN definite diagnostic criteria, would sacrifice the benefits of 
early detection gained by monitoring with MRI. Such an approach was successfully implemented in at least 3 patients with PML 
compatible MRI changes but negative CSF JCV PCR.
69,71
 In these 3 patients managed as if the diagnosis was established, two had 
subsequent detection of JCV in CSF on repeat sampling. In all patients the MR imaging evolved to a pattern compatible with 
development of PML with IRIS, helping to strongly support the diagnosis. Often asymptomatic patients later develop symptoms 
associated with IRIS, ultimately fulfilling traditional diagnostic criteria. 
 To date, serial quantitative JCV antibody determinations have too rarely been used to help consideration of possible PML in 
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difficult cases. Active JC virus disease including PML typically drives an increase in JCV antibody titers that confirms JCV related 
disease. Thus, even if viral DNA is not demonstrated in CSF, if compatible and evolving MRI lesions are associated with increasing 
systemic JCV antibody titers, this should provide significant support for diagnosis of PML.
87
 Use of this approach may not work in the 
face of prior immunotherapy, however, necessitating biopsy or presumptive diagnosis without confirmation. Brain biopsy remains the 
ultimate criteria when a definite diagnosis is required lacking detection of viral DNA in the CSF. However, with small pre-clinical 
lesions, it will be difficult to biopsy at the earliest stages, and should be only used judiciously when certainty about the diagnosis is 
clinically critical.  
 
 
Risk Mitigation Strategies Are Failing Us 
 A risk mitigation strategy was developed by Biogen/Idec following FDA requirements to protect patients from developing 
PML in the setting of natalizumab therapy.
88
  The fundamentals have been actively discussed, and variably applied. 
10,11,89-93
 However, 
the ideal of witnessing plummeting incidence of PML cases has not yet materialized. 
94
 We summarize our own detailed suggestions 
based on a most recent suggestionalgorithm 
95
 (101 McGuigan) and the data we are aware of in Table 3. We propose the surveillance  
be guided by the estimated risk, dichotomizing it into 2 groups: a) regular surveillance if the PML risk is ≤ 0.9/1000 and b) intensive 
surveillance if it is above 0.9/1000 patients. This approach allows simple adjustments when the estimated risks change or new risks are 
identified. (Insert: Recommendations)  
Shortcomings of risk stratification elements 
The substance of the three key risk stratification elements is known to have flaws that might help understand the suboptimal 
impact they exert. First, while JCV antibody is a predictor substantiating infection with the virus causing the disease., its imperfections 
increase with careful inspection. Unfortunately, JCV viremia and viruria can be present in antibody negative patients.
96
 Further, 
quantitative antibody analysis, while suggestive of more active infection with higher risk, fails to be predictive after prior 
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immunotherapy. While overall expression of antibodies inversely correlates with disease risk, some evidence that antibodies still may 
play a role in controlling this virus is emerging, reviving interest in vaccination strategies for JC virus or PML management.
42,97
 Thus, 
JCV antibody status falls far short of an ideal biomarker. Second, duration of therapy as a risk parameter is also flawed.  The measured 
variable is duration of time from from DMT natalizumab therapy start to clinical diagnosis of PML, which itself may be a 
considerable time after the first symptoms.
98
  The actual biologic interval of interest is time to brain infection with the virus. Through 
observations with more intense monitoring of pre-symptomatic high risk populations, we now realize that infection likely takes place 
at least 6 months prior to the clinical manifestations of disease, substantiated by observation of pre-asymptomatic lesions of PML on 
MRI scans, and by pre-symptomatic immunoglobulin elevations leading up to PML diagnosis.
29,82
 It is likely that the pre-symptomatic 
interval is even more variable related to the eloquence of clinical expression of lesions in different brain regions. For example, it 
seems given likely that brainstem lesions would more rapidly lead to symptoms compared with frontal lobe lesions. Thus, 
extrapolation about specifics of pathophysiology based on the crude interval from start of therapy to clinically symptomatic disease is 
quite imprecise. Recent critical analysis about the imprecision of the Biogen risk estimates for impact of duration of infection become 
even less meaningful, when the imprecision of biology reflected by the measure is considered more critically.
92
 Third and finally, the 
impact of prior immune suppression on risk is similarly quite poorly fleshed out in literature. It is fundamentally untenable that the 
specifics of type and duration of prior immunotherapy is of little consequence in determining risk on a biologic basis, yet this is at 
present a monolithic consideration. A dose of azathioprine would receive equal weight with long term cyclophosphamide therapy, yet 
impact on the immune system must be very different.  
Thus, current negative commentary on the precision of the present risk mitigation strategies is unsurprising, but perhaps 
clinically not so critical.10,92,99,100 
 
Considerations from the clinical decision process 
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While providing plausible sources of additional PML risk, none of the established factors truly drives appropriate clinical 
decisions by patients and their physicians about when they should use a drug with a recognized risk of PML. Consider the decision of 
a patient with aggressive relapsing remitting MS who is experiencing increasing neurologic disability. If a therapy has the possibility 
to halt disease progression in a majority of cases, but there is a slight moderate risk of death (~25% of the small number of PML 
cases) or instead,  the risks of therapy may sound reasonable to an individual with a risk affirmative approach to living. At present,  
weighing this decision is left to the patient and physician.
94
 The problem is really how to ethically relay the needed information so a 
patient can either accept the risk openly or reject it. {Kramer, 2017 #15776}Better ways to assure a balanced discussion are required 
as well as assuring that clinicians are enabled and reimbursed to spend the time necessary for this nuanced discussion. Therapeutic 
enthusiasts must not minimize the serious risks of therapy with PML risks, while timid clinicians should not fear offering this choice.    
 
Risk stratification with newer disease modifying MS therapies 
Even theThe crude risk mitigation developed for natalizumab is likely only truly applicable in relation to that drug. PML risk 
with other available and emerging DMT for MS (dimethyl fumarate, fingolimod, rituximab, ocrelizumab) is much lower,
89
 and while 
its presence must be acknowledged, it should not severely impact decision making where benefits can be accrued by implementing 
early and effective MS therapy. In the case of dimethyl fumarate, monitoring for lymphopenia appears likely to identify a higher risk 
group in whom alternate therapy should be sought. In that setting prolonged lymphopenia with absolute lymphocyte counts <750 
accounts for most cases, although the risk may reside particularly in the loss of CD8 cells critical to JCV control.
101
 Measurement of 
circulating lymphopenia however is not universally helpful. For fingolimod, this strategy cannot be applied since circulating 
lymphocytes decline while effective lymphocytic function appears largely normal.  Similarly, alemtuzumab associated risk for PML 
has not been demonstrated in MS patients yet despite marked impact on lymphocyte profiles. Alternatives to lymphocyte counts might 
include serial antibody measurements, or monitoring for circulating JC virus., The multiplex PCR that allows identification of 
Comment [c2]: this is not one of the 
strongest sections, and since we are asked 
to try to shorten the overall manusript, and 
it is a very superficial pass at these issues, I 
suggest we cut this... 
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emergence of prototypic virus that likely has enhanced risk of PML seems a plausible means of risk stratification, but has not yet been 
demonstrated to serve in this way.
23
 However, the low overall risk with alternative DMT makes it difficult to validate, and probably 
impractical to use as a stratification factor in practice. Other alternative PML risk stratification approaches under investigation in 
natalizumab associated PML include measurements of CD62L and lipid-specific IgM bands. 
102,103
At present similar logic applies to 
rituximab and ocrelizumab. These monoclonal antibodies directed against B cells have yet to demonstrate excess risk of PML in MS 
patients despite a large number of cases associated with rituximab when used in the setting of hematologic malignancies and other 
diseases with greater underlying risk of PML.
104,105
 The theoretical risk suggests clinical vigilance, but no other risk mitigating 
strategy can be recommended for PML at this time when using these emerging MS therapies.  
Thoughts on risk mediation based on what has been learned 
Ongoing consideration of additional risk mitigating factors that would aid risk assessment and be more predictive should be a 
theme of investigation . Technology that allows more detailed consideration of JCV specific immune control might more accurately 
reflect risk. Quantitative definition of the specifics of T cell recognition and response, as well as identification of the emergence of 
prototypic virus might well alert the clinician to a small subset of high risk patients in whom therapy would be foolhardy.  
The fact that the present system has largely deluded us all is evidenced by the lack of impact so far on the incidence of new cases. 
While the imprecision of the present risk model is likely in part to blame, the most likely cause is that risk monitoring and 
communication is either too inconsistently done to inform patients, or that they are choosing to continue to use natalizumab even when 
they have a significantly elevated risk. The overall good from added quality of life in successfully treated patients may well exceed the 
real harm to the smaller number of patients who unfortunately develop treatment related PML. To assure that our system is offering 
better outcomes overall, and that people are not being treated without proper understanding, we need better longitudinal understanding 
of both the risks and benefits of our therapies. 
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Development of therapeutics for auto-immune diseases including MS, genetic origin of immune disorders or neoplastic disease is in 
evolution, and optimizing these choices to include PML risk will require more detailed data than currently exists. For example, the 
relative efficacy of MS therapies, as well as their costs must inform prescribing patterns. Estimates of these factors are difficult to 
substantiate. These factors must be integrated with the risk of PML encumbered by various therapies. At present, natalizumab is 
known to have substantial risk, while there is evidence that both fingolimod and dimethyl fumarate elevate PML risk in MS patients 
slightly.
7-9,106-108
 Integration of these risks with relative tolerability and efficacy of the agents invites refinement of clinical skills of 
physicians, and challenges them to find ways to reduce the risks for all patients requiring any of these therapies.
106
 Calculation of all 
of these factors, and explaining them to a patient who must fit this evidence into a personal risk tolerance profile is a very difficult 
task. Better tools need to be developed to assist patients and physicians in meaningful ways to understand this and come to an ethically 
sound decision for the patient’s management.106 
 
 
Conclusion and future directions 
 The past decade has witnessed substantial progress in understanding JC virus and PML. The close observation and additional 
cases seen in multiple sclerosis patients has given the opportunity to enrich the molecular biology of JC virus, and to make some 
progress on likely evolution of risk and invasion of the brain. Enhanced identification of higher risk patients has allowed the evolution 
of use of MRI, such that detection of PML lesions prior to symptom onset is commonplace in high risk patients. Improved use and 
interpretation of MRI have proved pivotal for PML. However, the clinical management of MS patients remains challenging. 
Further, the outcomes from PML have markedly improved. While PML is still a serious and sometimes lethal disease, a majority of 
patients contracting it survive in settings where immune reconstitution is possible, and with early detection of disease, commonly 
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severe disability from PML can be avoided. However, we still are unable to detect individual risk precisely enough to give easy 
instructions about PML, and still settle for very early diagnosis to minimize injury.   
Meanwhile, the practical means to enhance communication about risk and help patients select the optimal approach to their illness 
tailored by their own willingness to take risk is an ongoing clinical challenge. It is especially important to be sure that it is not for lack 
of monitoring and acceptance of known risk that patients are developing PML. If on the other hand, patients have accepted the risks 
and continued therapy with full knowledge of risks and benefits, principles of ethical care have been served. Ultimately understanding 
the overall difference in outcomes of those who accept the risk with DMT and do well, compared to those who develop PML, should 
be understood and have acceptable value,  if the choice to use this therapy is to continue to be up to patients and their clinicians.  
The basis for such an analysis is the availability of credible data. PML is not a reportable disease, and detailed retrospective data 
gathering is laborious and incomplete. Registration of cases with systematic reporting of circumstances of the disease would allow us 
to study the impact of risk mitigation concepts. Development of widespread or universal data collection and consideration of cases 
could speed research on risk and outcomes, and allow more precise risk mitigation programs. We believe that while the mitigation 
strategies are not perfect, the largest failure is in not implementing changes in therapy when risk is known to be increaseelevated. It 
will be easier to implement changes in therapy when  With MS therapies that are comparably effective to natalizumab, we believe 
replacement of natalizumab in high risk patients should be more uniformly employed and should reduce the burden of this tragic 








Table 1 – Stages of JCV Infection Leading to PML 
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TABLE 1: Urinea Bloodb CSFc 
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Footnotes for Table 1 
a. Urine samples can be tested for JCV DNA to demonstrate a latent or persistent infection.   Approximately 30% or more of the population 
globally excrete JC Virus in the urine, viruria, without pathological effects in the kidney although very high levels of viral DNA can be present. The 
JCV archetype variant, unique arrangement of non-repeating nucleotide sequences in the non-coding control region or NCCR, is the most 
common in the urine. The JCV archetype variant is thought not to be neurotropic and is rarely detected in brain or CSF of PML patients.   
 
b.Blood samples are tested for antibody to JCV in either serum or plasma indicating prior exposure to JCV. Seroepidemiology of JCV has shown a 
global presence of JC Virus infection. However, multiple alterations throughout the genome can be found that have used to ‘Type’ JCV allowing 
studies to define geographical distribution and follow transmission in family members.  High levels of antibody or increasing levels of antibody, 
reported as a titer or index, usually indicate active infection from reactivation of latency or a new infectious episode. Antibody levels also may 
fluctuate so sero-positive or sero-negative status may change over time. Estimates that this conversion takes place in 2% to greater than 10% of 
the population annually. Also, rare seronegative individuals may experience JCV infection and not show or make antibody as evidenced by viruia 
or viremia.43   
Blood samples are also used to test cell compartments for JCV DNA as cell carriers for infection or persistence. Notably viral DNA has been found 
in CD19+/20+, CD34+ cells but not in CD 3 (T cells) or monocytes. 21 
c. CSF samples with detectable JCV DNA serve as the laboratory confirmation of PML diagnosis.   Quantification of viral DNA is reported as 
genome copies per ml.  Currently, the most sensitive assay has a limit of detection of 10 c/ml.23  Usually, the lower the copy number of viral DNA 
the better the PML prognosis.  Viral DNA in the CSF is the prototype variant with repeat nucleotide sequences in the NCCR thought to be derived 
from the archetype variant through deletion, duplication and rearrangement. This transformation from the archetype to prototype probably 
takes place before entry into the brain in lymphoid tissues like nodes or bone marrow.52,53 There can be multiple nucleotide arrangements of the 
NCCR in PML patients plasma, brain and CSF. However, generally no two PML patients demonstrate identical patterns although the same variant 
is found throughout an individual PML patient’s tissues. 41 
CSF samples also can be tested for intrathecal antibody to JCV that occurs in PML patients and may be used as a marker or sign of developing 
PML.43   
d. Antibody is measured by ELISA assay using viral major capsid protein, VP1 derived from the prototype variant, as antigen; result reported as 
titer 33or index34, depending on assay, reflecting the level of antibody response, usually IgG. Other VP1 variants have been reported that may 
have escaped immune control with mutations in the VP1 sequences that were identified in the CSF of PML patients with specific T cell responses 
so attributed as the potential PML causative variant.40 However, almost all PML patients with ELISA demonstrated antibody to JCV have the 
prototype variant in brain and CSF.    
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e. Viral DNA is measured using quantitative polymerase chain reaction specifically measuring copy number of viral genome DNA as c/ml;  
low=50c/ml; hi=>500c/ml. In MS/PML patients, the median c/ml is >100c/ml to <500 c/ml in a range of 10c/ml to 107c/ml 37  Primary infection is 






Table 2: Stages of Progressive Multifocal Leukoencephalopathy 
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T1 cortex 
        
 
1 Duration of pre-asymptomatic stage dependent on location in brain. Clinically silent regions like frontal lobes may harbor pre-asymptomatic 
infection for up to 41 wks in one documented case, while areas causing symptoms with small lesions will be detected in fewer months. Duration 
of this phase is consistent with symptomatic PML occurring up in the first 6 months after natalizumab discontinuation. 
 
2Four most helpful features suggesting a PML lesion in asymptomatic patients: subcortical location (involvement of U-fibers), T1 hypointensity, 
DW hyperintensity, and the presence of punctate T2-hyperintense lesions. Evolution of lesion on subsequent scans important to substantiating 
diagnosis.  
 
3 Typical of PML developing in untreated HIV/AIDS or highly immune deficient setting where virutally no immune response seen. Classically this 
symptomatic disease led to death within 6 months in most patients.  
 
4 PML with IRIS can also occur at the pre-asymptomatic and symptomatic phase where partial immune deficiency occurs (common in 
natalizumab MS at onset); punctate lesions (± CE) and T1 cortical bands probably indicate inflammation with or without CE. Prior cortiocsteroids 
reduce chance of CE without eliminating inflammatory response.  CE: Contrast enhancement 
 
5 PML with IRIS persists for up to 5 months or longer documented by late biopsy of lesions, and may require repeated therapy to suppress.  
 
6 Deaths from PML typically occur within 6 months of diagnosis, with survivors dying of other causes months to many years later, often hastened 
by underlying diseases, or the hazard of neurological disability and its complications.  
 
7 JCV DNA typically declines and often is undetectable after survival of PML. However, virologic cure does not occur, and CSF may continue to 










Table 3:  Protocol for PML surveillance in MS patients 
  
Monitoring steps for Patients  MRI Sequences 
  
Treatment Group PML risk S Anti JCV 
AB 









    FLAIR T2 DWI T1 T1+Gd PD/T2/STIR T1+Gd 
   
Immunmodulatory 
treatment  
    Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
All NTZ patients     Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
 Anti JCV negative NA NA  6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 




   
 Index <0.9 1 – 72M 0.1 – 0.6 R 6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
Index 0.9-1.5 1 – 36M 0.1 - 0.8 R 6M Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
37 – 72M 2 - 3 I  3-4 M PML Y6 Y7 Y - - - - 
Index >1.5 1 – 24M 0.2 – 0.9 R  Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 
25 – 72M 3 - 10 I  3-4 M PML Y6 Y7 Y - - - - 
JCV +ve, Previous 
Immuno-
suppression 
1-24M 0.3 - 0.4 R  Yearly MS activity Y2;3 (Y)4 Y5 Y Y8 Y9 




Abbreviations:  FLAIR = fluid-attenuated inversion recovery  ,recovery, DWI = diffusion weighted imaging, I = intensive surveillance, S = 
surveillance, T1   T1 + Gadolinium,  PD = proton density  , STIR = Short T1 inversion recovery; NTZ= Natalizumab, R = regular surveillance 
a Risk estimates from report of EMA, February 2016107 
MS: Monitor MS activity, justified by aim to provide DMT achieving “no evidence of active disease” (NEAD) for optimal clinical 
management of MS 
PML: PML Surveillance 
1Spine MRI is not indicated for PML monitoring, but may be used in monitoring MS disease activity, or if neurological exam suggests 
possible spinal cord localization of pathology 
2Rovira108:  Mandatory  a) Axial proton-density and/or T2-FLAIR/T2-w; b) 2D or 3D contrast-enhanced T1-w 
Optional a) Unenhanced 2D or high-resolution isotropic 3D T1w; b) 2D and/or 3D dual inversion recovery;   
    c) Axial DWI 
3Traboulsee109: Mandatory (Core)  a) Anatomic 3D inversion recovery–prepared T1 gradient echo Gd;   b) 3D sagittal T2WI FLAIR;   c) 3D 
T2WI;    d) 2D axial DWI;   e) 3D FLASH (non-IR prep) postGd 
Optional:  a) Axial proton attenuation;    b) Pre- or post Gd axial T1 spin-echo;    c) SWI 
4 Optional in Rovira et al and mandatory in Traboulsee et al 
5 Optional in Rovira et al 
6McGuigan95 et al and Traboulsee et al recommend FLAIR 
7Yousry83 et al recommend FLAIR or T2-w; there is no data suggesting superiority of one sequence over the other in this specific scenario 
8Spine Traboulsee et al  Mandatory a) Sagittal T2; b) Sagittal PD, c) STIR, or PST1-IR; d) Axial  T2 through lesions 
     Optional a) Axial T2 through complete cervical cord; Gd & post-Gd sagittal T1 
Rovira et al    Mandatory a) Dual-echo (PD and T2-w); b) SE and/or fast SE; c) STIR (as an alternative to PD-w); d) Gd T1-
w SE (if T2 lesions present)    
     Optional  a) Phase-sensitive inversion recovery (as an alternative to STIR at the cervical segment) 
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       Axial: a) 2D and/or 3D T2-w fast SE; b)GD T1-w SE 
 
















































Figure 1: Stages of PML pathogenesis 
 
1. Initial infection through ingestion and/or inhalation of virion particles may lead to subacute infection and stimulation of antiviral 
antibody. No formal study has been conducted however to document these events. 
 
2. In some individuals, approximately 30% globally, JCV infects the uroepithelium of the kidney and establishes a persistent or latent 
infection as evidenced by excretion into the urine with little if any pathological consequences.  
 
3.  JCV may escape into the peripheral circulation in some individuals and spread virions into lymphoid tissues including bone marrow 
establishing a latent infection that can be reactivated at times of immune suppression or modulation. 
 
4. CD34+ cells in the bone marrow can become infected.  Natalizumab forces consistent migration of CD 34+ cells to the peripheral 
circulation that continues for years during treatment. 
 
5. Some of the migrated CD 34+ cells differentiate in a lymphocyte pathway, predominately in B cell lineage. Some of these cells that 
may be latently infected use these cells as host for viral multiplication.  
 
6. Both DNA transcription factors like SpiB in the POU2A domain as well as miRNAs are temporally regulated by natalizumab and favor 
JCV multiplication in latently infected cells. Viral genome may undergo nucleotide rearrangement in the non-coding regulatory 
region from the urine associated archetype, less pathogenic form to the prototype, PML associated pathogenic form      
 
7. JCV multiplication takes place in these cell phenotypes that may be recognized by CD4 and CD8 immune clearance as well as 
contributions of anti JCV antibody. Some infected cells escape immune clearance. 
 
8. JCV can remain in circulating B cells, perhaps pre B cells, as well as non-cell associated, free virions in the circulation and traffic to 
the brain.  
 
9. JCV can enter the brain in infected cells or free virus via hematogenous routes and initiate infection in the target oligodendrocyte. 




10. PML initiates as virus begins lytic, necrotic oligodendrocyte infection with gradual spreading of virus as evidenced by growing lesions 
in a multifocal pattern. a)represents MS lesions in PML patients treated with natalizumab; b)cortical white matter lesions with 
punctate lesions just below that are typical in PML and c)PML lesions in U fibers near the cortex. 
 
 
Figure 2:   
Natalizumab associated PML in an MS patient A, C, E: FLAIR images; B, D, F: Enhanced T1w images 
Asymptomatic PML (A and B): Enhancing right frontal lesion with multiple smaller non enhancing punctate lesions (white arrow) 
PML and IRIS (C and D): The lesion has enlarged on FLAIR and the enhancing area has increased; note the enhancing punctate 
lesions bilaterally (white arrows) 








 Risk biomarkers for PML must be expanded and made more accurate 
 Enhanced global data collection on cases of PML should be pursued to inform risk assessment and outcome analysis 
 Recommendations for surveillance should be geared to risk profile 
 Lower risk patients(<0.9 cases of PML/1000 exposed)  should receive routine assessment for MS disease activity as part of 
disease modifying therapy selection and refinement as well as PML surveillance 
 Higher risk patients (>0.9 cases of PML/1000 exposed) should undergo enhanced PML monitoring with more frequent MRI 
and antibody index assessments 
 Updated risk assessments should be available as output from the surveillance network allowing best practices refinement of 
practice 
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Reviewer #1: This is a revised version of the original manuscript, which was entitled: JC Virus, 
PML and Therapies for MS: Weighing the benefits and the Risks. The manuscript has been 
improved in a number of points, but still the three major aspects: a) historic summary of the still 
sketchy understanding of PML pathogenesis (see ref 42 for details)  with respect to virology and 
immunology ( see ref 18 and 33 and 37 for extensive molecular data on virology), b) use of 
natalizumab in MS and dealing with the PML risk and what can be learnt from that, and c) how 
to use MRI as a means of early diagnosis and management, remain in many respects superficial 
and/or speculative. The title now includes "...risks associated with therapies for MS", but the 
focus is almost entirely on natalizumab. Many of my original comments still apply, and I will not 
repeat these here, but list only some new points below: 
 
- In the introduction it is mentioned that the PML incidence in patients, who are on long-term 
treatment - it is not defined what long term means (24 months or longer is the currently used 
definition) - and are JCV antibody (ab) positive is at least 1 in 70 (Biogen data for highest risk 
category of patients and ref 71). It is not clear how the authors come up with this number. There 
are approximately 150.000 patients, who are being treated or have been treated with natalizumab, 
and somewhere between 700-800 PML cases have occurred. The majority of patients has 
received more than 1 year of treatment, and according to the above figure, one would expect 
2000 cases or more. The high risk patients are ones with >24 months of therapy, antibody 
positive and a history of prior immune suppressive treatment. That number is not 150,000. To 
avoid misunderstandings. I believe that >700 PML cases, >20% of these with fatal outcome and 
many with severe remaining disability after recovery are very serious, but the numbers that are 
given are not correct and would not be acceptable in my view. . As of Sept 2017 there are 749 
cases in Biogen report, so we have indicated >750 cases confirmed.  
1.  
- There are still a number of statements like the one in the introduction: "1. the molecular 
aspects of pathogenesis and cell-specific JCV infection leading to PML that may be 
generally applicable but also that specifically relate to unique pathophysiological of 
natalizumab", that are imprecise and difficult to grasp.(see text for changes) 
 
- Another: "It may be time now to consider PML not just as a rare disease but as a 
substantial significant  neurological complication in certain high risk populations". In 
HIV infection/AIDS, the drop of PML has been dramatic, and while there are a number 
of treatments (biologicals, small molecules, transplantation), which are accompanied by 
PML risk, it still remains a very rare to rare condition. Natalizumab-treated MS patients 
may be the only exception, possibly also CD20-directed B cell-depleting therapies in 
hematologic malignancies and rheumatoid arthritis. In the context of the latter it is 
interesting that PML has been associated with CD20 depletion in those conditions, while 
anti-CD20 antibodies that are widely used in MS have not yet shown any significant risk 
to develop PML. It would be important to comment on findings like this in a manuscript 
that tries to link PML pathogenesis to a certain treatment and in a specific disease, i.e. 
MS. (It should be noted that PML is not a reportable disease so the incidence of PML 
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clinical studies that are immune modulatory or lead to immune deficiency have PML risk 
mitigation plans in place. PML continues to be diagnosed in HIV-1 infected patients but 
not always reported as is the case in patients with other underlying diseases that place 
them at risk of PML.   
 
- The statement on page 4: "An increase in antibody titer or index indicates an active 
infection". As I already stated in my last review, there is no evidence for that.(The 
operative word here is ‘increase’ in antibody titer, that denotes a prior lower titer/index 
that rises over a time period. This is based on many viral infections in which there was an 
‘acute’ serum sample taken during initial clinical symptoms and the later when symptoms 
gradually subside or ‘in convalesence’. This is fundamental virology, recently 
exemplified in Zika infection and before in West Nile infections).  In fact it is not known 
what a high index means. (published data describes patients with a high index >1.5 have 
a greater risk of PML. See current Lancet Neurology paper from Biogen statisctians with 
more details).   Patients, who show shedding of JCV into the urine - approximately 40-
50% (perhaps more like 30%)of all JCV-infected individuals - also must have active 
infection, but it is not known if this is linked to a high JC ab index, whether non-shedders 
can become shedders, and what the pathological - if there are any - consequences of viral 
excretion are. The reasons why some patients start with a high JCV ab index and usually 
stay high, while others show a low index after seroconverting, i.e. from the beginning, 
and then usually stay low are also not known. If high and rising antibody indices 
indicated active infection or higher viral loads or change of viral types from wild type to 
PML strains, then one would expect that some data for one of these, e.g. higher viral 
DNA load in the blood, would have been described, but I am not aware that this is the 
case. It is of course also possible that it has not been examined yet, but at any rate, the 
meaning of high JCV ab indices and how they may predispose to PML are not known. 
The authors therefore should either be more specific with their statements or avoid them. 
The text includes the current knowledge of this area. Further discussion on this topic may 
be worthy of a more specific review.  
 
- Further down: "the VP1 gene can be hypervariable...". Hypervariable means that a gene 
is frequently mutated, as is for example the case in immunoglobulin genes after 
rearrangement and affinity maturation. My understanding is that mutations in VP1 are 
overall - when compared to capsid proteins of other viruses - rare and that only relatively 
few mutations have been described in VP1 in PML- and granule cell neuronopathy 
(GCN) variants of JCV. (The VP-1 gene is hypervariable which is the basis for the 
‘typing system’ of JCV variants that was described in the mid 1990s, see reference27 and 
references therein. Also the Type of JCV variants, based on VP-1 sequences have a clear 
geographic distribution with a number of epidemiological studies identifying regional 
JCV infections.  
 
- "So, it is not surprising that any one PML patient may have multiple representations of 
VP1 at any one time". Again, what is the evidence for this statement? While in theory 
this is a possibility, there is very little data on it. A patient, who develops PML should 
have wild type (wt) and PML variant at the same time, but presence of multiple PML 








sequencing of JCV DNA in PML patients as well as the JCV Compass paper Jensen, P et 
al J Leukocyte Biol 65: 1999 and Jensen P et al J NeuroVirol 7: 2001).  At least one of 
the two papers that are cited in the next sentence does not provide evidence for that, but 
only mention a GCN variant, but not presence of multiple PML/GCN variants. (There are 
variations in the VP-1 gene associated with JCV/GCN at a region near the 3’ intergenic 
region of the genome. There is no unique variation in this region that describes GCN but 
variations over a number of different nucleotides (ref 15). With a limit of 100 references, 
it is difficult to list all the details and references on these topics. For a more complete 
review, see Ferenczy M et al in Clin Micro Review,25; 471-506, 2012.  
 
- The description as to which immune components are important in maintaining control 
of JCV infection or are involved in recovery from PML is very sketchy. If one considers 
the spectrum of conditions that lead to PML - ranging from different types of hereditary 
immunodeficiencies over drugs with more or less specific effects on the immune system 
to autoimmune diseases with different pathogenetic mechanisms - it is clear that neither 
CD4+ or CD8+ T cells nor antibodies and B cells alone are important, but that the issue 
is more complex. The authors brush over this area in a very superficial way that does not 
take into account the substantial progress that has been made in recent years. See ref 29 
for a more detailed discussion on immunity. This paper is from Roland Martin’s lab in 
Zurich who is a highly regarded neuroimmunologist.  
 
- What is meant with: "... temporal upregulation of factors that highly favor JCV 
growth"? The szenario that transcription factors and recombinases of B cells may 
participate in mutation is reasonably supported, but that natalizumab or factors associated 
with it favor JCV growth has not been described to my knowledge. See reference 41 from 
L. Kappos group in Basel and Lindberg R from that group as well as ref 40, 42.  
 
- After describing the JCV biology and possible factors that may lead to PML under 
natalizumab or in general the authors jump abruptly to MRI. Not even the diagnostic 
requirements for PML are introduced before that. (A transitional sentence was inserted to 
smooth this transition. Because of space restrictions, we had to cut out an entire section 
on diagnosis from earlier drafts, but this is well covered in other reviews) 
 
- The statement, "Non-specific white matter lesions are common, and in MS patients lesions may 
be part of the underlying disease", is again imprecise or wrong. Lesions in certain typical 
locations (which overlap with those, where PML occurs) are characteristic for MS and the most 
important diagnostic finding. They also pose a major problem in identifying early PML lesions 
in a brain that shows often a high lesion load already. Having worked and published over the last 
20 years on the various aspects of the imaging of MS (diagnosis, visualisation, outcome 
measures) we are of course aware that there are typical patterns of MS lesions. However, the 
specificity is limited as they can occur in healthy individuals, reflect silent progressing disease 
(small vessel disease or other inflammatory or other disorders. In Yousry et al. 2012, we 
highlighted the problem of identifying PML lesions in a brain with MS lesions. To improve 
clarity, we have modified as follows: “Small lesions can be difficult to differentiate from MS 







- In many parts of the manuscript, it is clear that none of the authors is an expert in MS. To 
include this would certainly have helped. (TY member of MAGNIMS) 
 
- "It is fundamentally untenable that the specifics of type and duration of prior immunotherapy is 
of little consequence in determining risk on a biologic basis, yet this is at present a monolithic 
consideration". This sentence is very cryptic. Such statements do not help, but only confuse the 
reader. (We think this is quite a precise statement.  We could say that based on widely varying 
mechanisms and potency of immunotherapy, they are very likely to have quite different impact 
on the immune system or evolution of JC virus, yet they are at present considered as having only 
one possible contribution… this takes more words and seems less impactful than our current way 
of saying this…) 
 
- "If a therapy has the possibility to halt disease progression in a majority of cases, but there is a 
slight risk of death (approx. 25% of the small number of PML cases) or instead, the risks of 
therapy sound reasonable to an individual with a risk affirmative to living." First, the sentence is 
incomplete. (modified to help the reader see full sentence) Second, the authors swing between 
dramatizing (more than 1 in 70 patients treated with natalizumab have suffered from PML; in the 
introduction) to trivializing the risks of natalizumab in this sentence here. (we are satisfied the 
reviewer now understands the tension that presents itself to the patient and physician.  This 
reviewer is not in the camp of “risk affirmative”  but surely must recognize that superior MS 
management might balance risk of PML for some with worsening disability (and death?) from 
MS)  No other MS treatment has caused remotely as many deaths as natalizumab, and that in a 
disease that affects young individuals without a major compromise of life expectancy. > 700 
PML cases is a substantial number, and, as already indicated before, if patients do not die from 
PML they often have severe remaining disability. Furthermore, a series of other drugs is now 
available that are as effective or more effective than natalizumab. (these drugs were not available 
at the time we wrote this, and their track record is very short and incomplete at present) Finally, 
if one considers a new measure of MS disease activity, NEDA = no evidence of disease activity 
based on relapses, disability accrual and MRI findings, then the fraction of MS patients, who 
fulfill NEDA criteria after two years, which is a short period in the course of MS, is only 
approximately 45%. Again, it would have helped if an expert in the field of MS had contributed 
to the manuscript. As an aside, NEDA is referred to as NEAD further down. (please note this 
manuscript was altered to focus on PML and not on MS treatment at the request of the editors) 
 
- "Alternatives to lymphocyte counts might include serial antibody measurements, or 
measurements of circulating JC virus." Neither of these would be meaningful from my 
perspective, or at least there is no data to suggest that. Furthermore, the authors should have at 
least mentioned a recently described marker, CD62L expression.  (This is now mentioned and 
referenced) 
 
- The information in table 3 for PML surveillance is in part helpful, but too complicated. Since 
the spine MRI is not routinely done for PML surveillance, it could be left out. The brain MRI 
should consider both, continued monitoring for new MS activity and at the same time indications 








could be conveyed in much simpler and easier to grasp form. In the higher risk strata, the 
information how often JCV ab indices should be measured are not stated. 
We have stated in the legend: “1Spine MRI is not indicated for PML monitoring, but may be 
used in monitoring MS disease activity, or if neurological exam suggests possible spinal 
cord localization of pathology”. We suggest this table to be used for surveillance of PML; this 
surveillance is integrated in the routine and regular scanning for MS activity, which does include 
spine imaging. Leaving out the spine will make it incomplete, thus limiting its practical usage. 
We prefer to keep the table because we suggest it to be used in the routine setting and to not 
affect the word count. 
 
- Despite my mentioning it already in the first version, Fig. 2 on page 30 still does not have 
labels on the various panels, i.e. it is not clear what A, B, C, etc. is.  
The lergend states: “Natalizumab associated PML in an MS patient A, C, E: FLAIR images; B, 
D, F: Enhanced T1w images”. The image when viewed on the computer screen has the letters, 
but on printing this did not show for some reason, so this reviewer must have printed the copy 
used for review. We will try to assure that a printed version also shows the lettersThe letters and 
arrows now print on our printer without difficulty as formatted. 
 
- The manuscript does not mention treatments of IRIS including the CCR5 inhibitor maraviroc, 
which would be of interest, and neither are the previously proposed treatments, mirtazepine, 
mefloquine and others discussed. Management has been reviewed elsewhere and is referenced. 
However, we agree with this reviewer that having completely cut the management discussions is 
a shortcoming in the manuscript. To address this we have added 5 sentences with appropriate 
references to frame the recommendations and controversies of PML and IRIS management 
including several 2017 references to guide the interested reader.  
 
 
Reviewer #2: Dr. Clifford and colleagues review the current state of knowledge about the 
pathogenesis of PML with an emphasis on what we have learned from the experience with 
natalizumab. They also expand on existing recommendations regarding risk mitigation with the 




1) The discussion of immune protection against JCV and PML development makes little 
comment on the potential role of neutralizing antibody. For completeness, a sentence or two 
regarding its potential role should be included.  Bottom of Page 5 now has sentences on role of 
antibody in neutralizing JCV infection.  
 
2) The authors cite Buckle's paper in which the investigators were unable to amplify JCV from 
MS brains studied. On the other hand, there have been a fair number of papers that have 
demonstrated JCV DNA in low copy numbers in the brains of individuals without PML. This 
should be noted, though the authors may want to comment on the absence of evidence of viral 
replication in these brains. Bottom of page 6 and top of page 7 now has sentences addressing 
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JCV latency in brain and includes a NEW reference  (Tan CS, Ellis LC, Wuthrich C et al. JC 
virus latency in the brain and extraneural organs of patients with and without progressive 
multifocal leukoencephalopathy. J Virol. 2019; 84:9200-9209. 
 
3) The authors posit that evolving MRI lesions with PML may occur in tandem with increasing 
antibody titers. While the Gorelik paper (Ann Neurol 2010) was unable to demonstrate a 
correlation between the JCV antibody index and levels of JCV urinary shedding, a recent 
publication (Berger JAMA Neurol 2017) showed that higher antibody levels were associated 
with higher copy numbers of virus in the kidney and broader distribution of the virus 
systematically.  The latter is supportive of their contention regarding rising antibody index levels 
correlating with PML evolution. Reference to this recent manuscript was added.  
 
4) The authors might want to include data from studies of MS patients' and treating physicians' 
risk tolerance in their discussion of the clinical decision process. This is an important topic that 
the manuscript can’t support full discussion around, but we have added a sentence and current 
reference (Kramer et al 2017) to give the interested reader an entrance to that literature. 
 
5) In Table 2, the authors should clearly define what they mean by "duration". Excellent point, 
that we have addressed by more specifically defining the term “DURATION”.  
 
6) The "punctate lesions" are included only in the PML IRIS category, but in this reviewer's 
experience, it has been observed in PML without IRIS. Is there data to suggest it is specific for 
PML-IRIS? If so, include it. 
We suggest that the occurrence of the punctate lesions in natalizumab treated patients is an 
indication of IRIS. We haven’t found reports describing them in non-MS patients, but although 
unusual wouldn’t exclude that this could happen, particularly in more recent HIV cases occurring 
during immune reconstitution. Our consideration of this includes recognizing that IRIS as 
defined by enhancing MRI lesions is a crude measure of actual inflammatory responses in the 
brain (particularly where steroids have been used in mistaken efforts to treat MS exacerbation or 
in pre-emptive IRIS therapy post PLEX).  We suspect that the presence of these lesions may be a 
more sensitive indicator of IRIS than enhancement, and it is because of this that we think they 
may be particularly important.  
 
7) In Table 3, the suggestion is that the JCV antibody be obtained every 6 months. In this 
reviewer's institution, it is done every 3 months in all patients and once positive, is regarded as 
positive, regardless of the nature of subsequent tests. They might consider offering a range of 3-6 
months.  We recognize that recommendations could be graded. Given the very small rate of 
change, and our understanding of the duration of latency of JC virus leading to clinical PML, we 
believe q 6 mo is adequate, but would have no objection (save cost) to more frequent testing. We 




Reviewer #3: This major revision improved the manuscript significantly. Esp. the new tables and 












Reviewer #4: The authors have prepared a restructured manuscript, focussing on their key 
expertise and mainly defining natalizumab (NAT)-associated PML. It is a true pleasure to read 
the well developed virological part.  
 
on page 9 (in landscape Format) 'asymptomatic PML' is used as subheading - I would consider to 
denote 'presymptomatic   Agree to change both in heading and Table 2 – a fine point but 
reasonable.  
JCV infection' indicating that PML will most probably unfold if Treatment with NAT is not 
stopped.   
same page lane 5 Ref 101 McGuigan has to be incorporated 
 
on page 7 pp early MRI is handled. Dr Yousry was instrumental in examining the MRIs from the 
first pivotal NAT study patients. I wonder why he does not comment whether Long - Standing 
NAT Administration often afflicts brainstem and infratentorial structures with PML  
 
on page 15 conclusion, paragraph 3: I would clearly support an alternative view, namely 
switching high-risk NAT-treated MS patients to alternative meds. The easiest Approach is 
certainly Bcell depleting ocrelizumab which is approved in US and awaited in Europe. But also 
fingolimod, alemtuzumab and daclizumab may qualify as serious follow-up medication post 
NAT. When you have seen dozens of NAT PML MS patients and their partially poor outcomes, 
there is  a clear need to stop this Russian roulette. We were criticized in making MS therapeutic 
recommendations, so had removed this. I agree that the viable options call for changing therapy 
when risk is clearly rising in patients. A sentence was added just before the description of 
alternate MS therapies recommending routine switching to alternate therapies as risk is 
increasing relative to natalizuamb. 
 
In central Europe a vaccination using recombinant JCV is under regulatory approval - it may be 
worthwile to comment on this in the conclusion. Alternatively key peptides with the 
immunogenic epitopes have been developed. 
The development of either antibody directed or T cell mediated immunization/vaccination is now 
considered more relevant. However, prophylactic or therapeutic use of vaccination against directed JCV 
peptides for wxample bring challenges to define the target groups either as those at PML risk based on 
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Figure 1
Click here to download high resolution image
 Figure 2:   
Natalizumab associated PML in an MS patient A, C, E: FLAIR images; B, D, F: Enhanced T1w images 
Asymptomatic PML (A and B): Enhancing right frontal lesion with multiple smaller non enhancing punctate lesions (white arrow) 
PML and IRIS (C and D): The lesion has enlarged on FLAIR and the enhancing area has increased; note the enhancing punctate lesions bilaterally (white 
arrows) 
Post PML (E and F): Further enlargement of the lesion on FLAIR and presence of T1 hyperintense cortex (white arrow)  
Figure 2 - Letters show in Word, not PDF
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